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CYTOTOXIC EFFECTS OF Phyllanthus watsonii AIRY SHAW EXTRACT        
IN COMBINATION WITH 5-FLUOROURACIL ON HUMAN COLON 
CANCER CELLS 
ABSTRACT 
Colorectal cancer (CRC) is one of the most common cancers that affects both men 
and women in Malaysia and is considered as one of the leading causes of death in the 
world. The chemotherapeutic agent that is used to treat CRC is usually 5-Fluorouracil    
(5-FU). However, the resistance of CRC cells to this drug and the side effects caused by 
this drug have prompted new strategies to overcome the shortcomings. The aims of this 
study are (i) to investigate the cytotoxic effects of Phyllanthus watsonii ethyl acetate 
extract (PW-E) in combination with 5-FU on human colon cancer cell lines HT-29 and 
HCT-116, (ii) to evaluate the possible interaction (synergistic, antagonistic or additive) 
occurs during combination between PW-E and 5-FU in their cytotoxicity based on the 
median-effect principle, and (iii) to determine the potential cell death mechanisms via 
apoptosis that is triggered by the combination of PW-E and 5-FU. The cytotoxic effects 
of PW-E, 5-FU and PW-E/5-FU combination on HCT-116 and HT-29 after 72 hours of 
were determined by Neutral Red Uptake (NRU) assay. The IC50 of PW-E, 5-FU and PW-
E/5-FU combination (at a ratio of 3:1) on HCT-116 cell were 1.522 ± 0.16 µg/ml, 1.588 
± 0.46 µg/ml and 1.482 ± 0.25 µg/ml respectively while the IC50 on HT-29 were 0.030 ± 
0.003 µg/ml, 19.70 ± 1.72 µg/ml and a combination of 0.03 µg/ml of PW-E and 10.0 
µg/ml of 5-FU respectively. By combining PW-E with 5-FU, lower dose of drug was 
needed, indicating that the cytotoxicity effect of 5-FU towards the cancer cells was 
enhanced in the presence of PW-E. Our result also shows that the Combination Index (CI) 
of PW-E/5-FU combination analysed by Compusyn 1.0 software was < 1 on both HCT-
116 and HT-29 cells. This indicates that PW-E/5-FU combination exerts a synergistic 
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effect on both CRC cells. In addition, PW-E/5-FU combination is selectively cytotoxic 
towards the CRC cells in comparison with the normal lung fibroblast MRC-5 cells. Drug 
Reduction Index (DRI) for PW-E/5-FU combination was measured on how much (-fold) 
the dose of a drug or agent in synergistic combination may be reduced at a given effect 
level compared with the dose of each drug alone. The DRI value for PW-E/5-FU 
combination on both HCT-116 and HT-29 is > 1 and shows that the combination is 
favourable in terms of clinical therapy. Morphological assessment by Acridine Orange / 
Ethidium Bromide (AO/EB) double staining showed that cell death mainly occurs by 
apoptosis instead of necrosis. Increase in caspase-3 activity was observed in CRC cells 
treated with PW-E/5-FU combination. PW-E was subjected to Liquid chromatography-
mass spectrometry/mass spectrometry (LC-MS/MS) analysis and six main compounds 
were identified. The compounds detected were quercetin, kaempferol rhamnoside, 
kaempferol glucoside, ellagic acid, hyperin and strictinin isomer. In conclusion, herb-
drug combination enhances the cytotoxic activity of 5-FU towards colorectal cancer cells 
and the cell death is mediated by apoptosis.  Hence, further studies should be done to 
understand further the interactions between the herb and drug. 
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KESAN SITOTOKSIK EKSTRAK Phyllanthus watsonii AIRY SHAW 
DALAM KOMBINASI BERSAMA 5-FLUOROURACIL TERHADAP SEL 
KANSER KOLOREKTAL MANUSIA 
ABSTRAK 
Kanser kolorektal (CRC) merupakan salah satu jenis kanser yang paling kerap 
dihidapi oleh lelaki dan juga wanita di Malaysia dan juga merupakan salah satu penyebab 
kematian yang paling utama di seluruh dunia. Agen kimoterapi yang sering digunakan 
untuk merawat CRC adalah 5-Fluorouracil (5-FU). Tetapi, disebabkan oleh daya 
ketahanan sel CRC terhadap agen tersebut dan kesan sampingan yang dialami akibat 
penggunaan agen ini, stategi baru harus diformulasikan bagi mengatasi batas keupayaan 
agen kimoterapi ini. Tujuan kajian ini adalah untuk (i) mengkaji kesan sitotoksik ekstrak 
etil asetat daripada daun Phyllanthus watsonii yang digabungkan dengan 5-FU terhadap 
sel-sel CRC iaitu HT-29 dan HCT-116, (ii) untuk mengenal pasti interaksi (sinergi, 
antagonistic atau tambahan) yang terhasil apabila PW-E digabungkan dengan 5-FU 
terhadap kesan sitotoksisiti berdasarkan kepada prinsip kesan-median, dan (iii) untuk 
mengenalpasti mekanisma kematian sel yang dicetuskan oleh gabungan dos PW-E dan  
5-FU. Kesan sitotoksik oleh dos tunggal PW-E, 5-FU dan dos gabungan PW-E dan 5-FU 
terhadap sel CRC HCT-116 dan HT-29 setelah 72 jam rawatan telah dikenalpasti melalui 
eset sitotoksik “Neutral Red” (NR). IC50 bagi PW-E, 5-FU dan kombinasi PW-E/5-FU 
pada nisbah (3:1) terhadap sel HCT-116 adalah masing-masing 1.522 ± 0.16 µg/ml,                 
1.588 ± 0.46 µg/mL and 1.482 ± 0.25 µg/ml, manakala IC50 terhadap sel HT-29 pula 
adalah masing-masing 0.030 ± 0.003 µg/ml, 19.70 ± 1.72 µg/ml dan campuran 0.03 µg/ml 
PW-E serta 10.00 µg/ml 5-FU. Dengan menggabungkan ekstrak PW-E dan 5-FU, dos 
ekstrak dan ubat telah dapat dikurangkan menandakan bahawa kesan sitotoksik agen 
kimoterapi tersebut telah dipertingkatkan. Nilai Gabungan Indeks yang dianalisis oleh 
 vi 
perisian Compusyn 1.0 menunjukkan nilai < 1 bagi kombinasi PW-E/5-FU yang diuji 
terhadap kedua-dua sel HCT-116 dan HT-29. Ini menandakan bahawa PW-E 
menyebabkan kesan sinergi apabila digabungkan dengan 5-FU terhadap sel CRC. Selain 
itu, kombinasi ubat dan ekstrak tersebut juga didapati lebih memilih ke arah sel CRC 
berbanding sel paru-paru MRC-5. Indeks Pengurangan Dos Ubat (DRI) telah diukur 
berdasarkan berapa kuantiti dos bagi kombinasi ubat dan ekstrak yang memberi kesan 
sinergi yang boleh dikurangkan tetapi masih memberi kesan yang sama seperti apabila 
ubat atau ekstrak digunakan secara berasingan. Nilai DRI bagi kombinasi PW-E/5-FU 
terhadap kedua-dua sel HCT-116 dan HT-29 adalah < 1, memberi indikasi bahawa 
kombinasi tersebut adalah bersesuaian dalam aplikasi terhadap terapi klinikal. Penilaian 
morfologi melalui perwarnaan dengan akridin oren dan etidium bromide AO/EB 
mendapati bahawa kematian sel adalah disebabkan apoptosis, bukannya nekrosis. Aktiviti 
caspase-3 juga menigkat apabila PW-E dan 5-FU digabungkan berbanding apabila ubat 
dan ekstrak digunakan secara individu. Kesimpulannya, gabungan ubat-herba 
meningkatkan kesan sitotoksisiti 5-FU terhadap sel kanser kolorektal. Interaksi 
sinergistik juga dapat dilihat apabila ekstrak digabungkan bersama agen kimoterapi 
dapam proses mematikan sel kanser. Kombinasi tersebut juga lebih kearah membunuh 
sel kanser dan meingkatkan aktiviti caspase-3 menandakan bahawa proses kematian sel 
meningkat. PW-E disubjekkan ke atas analisa LC-MS/MS dan enam sebatian utama dapat 
dikenalpasti. Sebatian-sebatian yang dikesan adalah kuercetin, kaempferol rhamnosida, 
kaempferol glucosida, asid ellagik, hiperin dan isomer striktinin. Kesimpulannya, 
kombinasi herba-ubat meningkatkan lagi aktiviti sitotoksik 5-FU terhadap sel kanser 
kolorektal dan kematian sel adalah disebabkan oleh apoptosis. Justeru, lebih banyak 
kajian harus dilakukan bagi memahami lagi interaksi antara herba dan ubat. 
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CHAPTER 1: INTRODUCTION 
According to the World Health Organization (WHO) in 2017, cancer is one of the 
leading causes of death worldwide and was to be blamed for the death of 8.8 million of 
the world population in 2015. American Cancer Society defines cancer as a group of 
diseases characterized by out-of-control growth of the cells. The uncontrolled cell 
division harms the body  by forming lumps or masses of tissues called tumours which can 
either be benign (accumulate in only one part of the body) or malignant (spreading to 
other parts of the body and destroying healthy tissues) (Lodish, 2000). 
 
One of the most common cancers that affects both men and women is colorectal 
cancer (CRC). According to the National Cancer Registry Report, colorectal cancer is the 
most common cancer among the men and the third most common among women  reported 
in Peninsular Malaysia (Lim et al., 2008). The cancer starts either in the colon or the 
rectum and is found on the epithelial lining of the large intestine or rectum. Rectal 
bleeding, pain of the abdomen, anemia, occult bleeding (gastrointestinal bleeding that is 
not visible) and change in the bowel habit are some of the symptoms of CRC (Majumdar 
et al., 1999). Early detection of colorectal cancer symptoms through intensive case-
finding, raising awareness of the public and an open-access facility of sigmoidoscopy can 
help in decreasing the mortality rate of CRC (Mulcahy & O’Donohue, 1997). 
 
There are various types of cancer treatments available nowadays. Treatments 
depends  on the type and stage of the cancer. American National Institute of Health (2015) 
stated that most patients undergo combination treatments such as surgery with 
radiotherapy or chemotherapy and some might only need a single treatment such as either 
surgery or chemotherapy.  
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In the treatment of colorectal cancer, 5-Fluorouracil (5-FU) has been the focal 
drug used during chemotherapy (Carethers et al., 2004). Studies on several human colon 
cancer cell lines shows that 5-FU cause the cell death by promoting apoptosis (Violette 
et al., 2002). However, several disadvantages arise in the use of 5-FU in colorectal cancer 
chemotherapy, namely drug resistance and severe side effects such as irritation, reddening 
and excessive lacrimation (tear production) of the eyes (Christophidis et al., 1979), 
diarrhea, nausea and also low blood count in patients. Cardiac toxicity has also been 
associated with the use of 5-FU in cancer treatment (Freeman & Costanza, 1988). 
Therefore, researchers are finding better solution in improving colorectal cancer 
chemotherapy and overcome the disadvantages of using this drug.  
 
   One of the most widely used treatments for cancer is chemotherapy. 
Chemotherapy is the use of drugs to destroy cells, or commonly referred to as cytotoxic 
medication (Nordqvist, 2015). The agents used in existing clinical practice have played a 
substantial role in reducing mortality/morbidity and in increasing patient’s quality of life 
(Suggitt & Bibby, 2005).  During chemotherapy, patient will either be given only one 
specific type of drug (monotherapy) or a combination of more than one type of drugs 
(combination therapy). Chemotherapy drugs works by disrupting the cancer cell’s 
capability to divide and reproduce (Nordqvist, 2015). Despite the recent advances of early 
cancer diagnosis and the improvement in clinical protocols for cancer treatment, the 
development of antineoplastic agents that combine the effectiveness, safety and 
convenience for the patient remains a great challenge (Ismael et al., 2008). However, one 
of the major problems in cancer chemotherapy is the toxicity effects of the drug (Prakash 
et al., 2013). In addition, the inability of the chemotherapy drugs to differentiate between 
healthy and cancer cells also cause adverse side effects such as stomach upset and hair 
loss (Fischer et al. 2003; Skeel et al., 2003). Most anticancer drugs also able to develop 
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multidrug resistance (MDR), have narrow therapeutic index, present unspecific 
biodistribution upon intravenous administration triggering undesirable side effects to 
healthy tissues. These drawbacks of conventional chemotherapeutic strategies commonly 
result in suboptimal dosing of chemotherapeutic agents, patients delaying and 
discontinuing treatments and even refusing to comply to the planned therapy (Ismael et 
al., 2008). 
Plant-derived compounds have long been an important source of numerous 
clinically beneficial anti-cancer agents as they have been proven to be effective and safe 
in the treatment and management of cancers (Prakash et al., 2013). Over 60 % of the anti-
cancer agents that are currently being used are derived from natural resources such as 
plants, marine organisms and microorganisms (Cragg & Newman, 2005). Convincing 
outcome in in vitro and in vivo preclinical studies have been reported to support the use 
of plant-derived compunds to treat several forms of cancers (Juàrez, 2014). There are four 
main classes of plant-derived anti-cancer agents that are currently being used clinically 
which are vinca alkaloids, epidophyllothxins, taxanes and camptotecins. These drugs 
have been used in the treatment of leukemias, lymphomas, breast, lung and Kaposi’s 
sarcoma and testicular cancer for more than 40 years (Juàrez, 2014). The search for anti-
cancer agents derived from plants began in the 1950s which lead to the discovery and 
development of vinca alkaloids isolated from the Madagascar periwinkle (Catharanthus 
roseus synonym Vinca rosea) and the isolation of cytotoxic podophyllotoxins from 
Podophyllum species (Cragg & Newman, 2005). These alkaloids and their semi-synthetic 
derivatives triggers the cancer cell death by blocking the metaphase stage of the cancer 
cells and also causes cell apoptosis (Juàrez, 2014). 
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Today, researchers have designed  a new method in cancer chemotherapy 
treatment and management, which is by combining chemotherapeutic agent with plant 
extract/compound. Positive result has been shown where combination of the 
chemotherapeutic agent with plant extract/compound helps in reducing side effects, 
overcoming drug resistance, and enhancing the effect of the anti-cancer drug by 
synergistic interaction.  
 
Hence, in this study, 5-FU was  combined with ethyl acetate extract of Phyllanthus 
watsonii Airy Shaw (family: Phyllanthaceae), an endemic plant species grows in 
Peninsular Malaysia and the cytotoxic and interaction effects of these drug-extract 
combination towards selected colon cancer cell lines were investigated. Previous studies 
showed that the P. watsonii ethyl acetate extract selectively inhibited the growth of human 
colon HT-29 cancer cells via apoptosis and cell cycle modulation. P. watsonii ethyl 
acetate extract also had been reported to induce apoptosis in breast MCF-7, ovarian 
SKOV-3 and cervical Ca Ski cancer cell lines and the cytotoxicity is selective towards 
the cancer cell compared to normal cells (Ramasamy et al., 2012; Ramasamy et al., 2013).  
Therefore, the specific objectives of this study were: 
i) to investigate the cytotoxic effects of individual Phyllanthus watsonii ethyl acetate 
extract (PW-E) and 5-Fluorouracil (5-FU) on human colon cancer cell line,        
HT-29 and HCT-116;  
ii) to evaluate the possible interaction (synergistic, antagonistic or additive) occurs 
during combination between PW-E and 5-FU in their cytotoxicity based on the 
median-effect principle; and  
iii) to determine the potential cell death mechanisms via apoptosis that was triggered 
by the combination of PW-E and 5-FU. 
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CHAPTER 2:  LITERATURE REVIEW 
2.1 Introduction to Cancer 
 In 2012, it was estimated that about 14.1 million new cases of cancer occurred 
globally (United Kingdom National Health Service, 2016). Cancers can be defined as a 
group of diseases caused by an uncontrolled growth of cells, which will then producing 
tumour and invade other parts of the body (WHO, 2013). Cancer can affect almost every 
parts of the body. Cancer can either be benign in which the cancerous cells accumulate in 
only one part of the body or malignant, the cancerous cells spreading to other parts of the 
body and destroying healthy tissues (Lodish, 2000).  
 
Cancers have their own traits, also known as the hallmarks of cancer, which are 
common in every types of cancer. The traits are biological capabilities attained during the 
multistep development of human tumours. The six hallmarks of cancer are (i) self-
sufficient in growth signals, (ii) evading apoptosis or programmed cell death, (iii) 
insensitive to anti-growth signals, (iv) sustained angiogenesis by stimulating the growth 
of blood vessels to supply nutrients to tumours, (v) having a limitless capability to 
multiply, and (vi) able to invade local tissue and metastasize to other tissues (Hanahan & 
Weinberg, 2011)  For a normal cell to progress into a neoplastic state, they acquire a 
succession of these traits. Radiotherapy, surgery, chemotherapy, hormone therapy, 
biological therapy and targeted therapy are some of the treatments used to cure cancer 
patients and the chances to cure is higher if the cancer is detected early (American Cancer 
Society, 2012; WHO, 2013).  
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2.1.1 Colorectal Cancer 
Colorectal cancer (CRC) is one of the most common forms of gastrointestinal 
cancer (Goh et al., 2005) and is the third leading cause of cancer mortality throughout the 
world (Yu & Li, 2006). According to the National Cancer Registry Report 2003–2005, in 
Peninsular Malaysia, CRC is the most common cancer among the men and the third most 
common cancer among the women (Lim, 2014). Cancer starts to develop either in the 
colon or the rectum and is found on the epithelial lining of the large intestine or rectum 
(Hong et al., 2015).   
 
Human digestive system including colon and rectum turns the food we eat into 
energy and packages the residue for excretion. Human colon is lined with rapidly dividing 
epithelial cells that are separated into individual compartment called crypts. A normal cell 
develops into a tumour when lesions occur on the individual crypts. The lesions on the 
crypts then progress into small adenomatous polyps and increase in size over time. These 
adenomas (benign tumour) can transform into carcinomas (malignancies that begin from 
the epithelial tissues), which will advance into metastatic colorectal cancer if left 
untreated (Kruzelock & Short, 2007). For a colorectal cancer to develop from an 
adenomatous polyp into an invasive cancer, it took approximately 8–10 years (Sung, 
2007; Ramasamy, 2012).  
 
 The abnormal structure and numbers of chromosomes in CRC is largely due to 
chromosomal instability. The loss of heterozygocity (loss of one of the two parental 
alleles in the chromosome, LOH) is one of the consequences of chromosomal instability. 
LOH usually happens in the tumour suppressor gene p53, adenomatous polyposis coli 
(APC) and SMAD family member 4 (SMAD4). Similar to other types of cancer, 
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neoplastic cells of CRC are also observed having mutation of oncogenes and p53 genes 
and genetic instability (Teoh, 2016). 
 
 Treatment of colorectal cancer is usually by surgery, followed by radiotherapy 
and then chemotherapy using the chemotherapeutic agents (Li et al., 2009). Most of the 
chemotherapeutic agents that had been widely used in cancer treatment are usually single 
isolate constituents or combinations of drugs. 5-Fluorouracil, raltitrexed, irinotecan and 
oxaliplatin  are some of the common chemotherapeutic agents used in the treatment of 
CRC (Gill et al., 2003). Among all the anti-cancer drugs listed, 5-Fluorouracil  has been 
mainstay in the treatment of CRC and is the first significantly effective monotherapy 
agent for stage 3 of CRC (Kruzelock & Short, 2007). 
 
2.1.2 5-Fluorouracil 
5-FU is an analogue of uracil with a fluorine atom at the C-5 position in place of 
hydrogen and having a structure similar to the pyrimidine molecules of DNA and RNA 
(Zhang et al., 2008). Because of its structure, 5-FU are able to be converted into 
fluorouridine triphosphate (FUTP), fluorodeoxyuridine monophosphate (FdUMP) and 
fluorodeoxyuridine triphosphate (FdUTP).  
 
FUTP, an active metabolite, disrupts RNA processing and function by being 
incorporated into the RNA, and lead to cell death. Meanwhile, FdUMP and FdUTP 
induces cell death by disrupting DNA synthesis (Longley et al., 2003). FdUMP forms a 
stable complex with thymidylate synthase (TS), thus inhibiting deoxythymidine 
monophosphate (dTMP) production. dTMP is essential for DNA replication and repair 
and its depletion therefore causes cytotoxicity (Parker & Cheng, 1990; Longley et al., 
2003). Many studies show that 5-FU has been shown to promote cell death in several 
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colon cancer cell lines through apoptosis (Petak et al. 2000; Longley et al., 2004; Borralho 
et al., 2007).  
 
2.1.3 Limitations and Side Effects of 5-FU 
Despite its advantages, clinical applications of 5-FU have been greatly limited due 
to drug resistance (Zhang et al., 2008). Resistance to 5-FU is a multifactorial event (Zhang 
et al., 2008). There are reports stating that 5-FU depends on the p53 tumour suppressor 
protein to trigger apoptosis (Pritchard et al., 1998; Bunz et al., 1999; Petak et al. 2000; 
Borralho et al., 2007). p53 is a tumour suppressor protein that aids in regulating feedback 
towards 5-FU. If p53 protein is disrupted, it will cause the colon cancer cells to be resistant 
to 5-FU and cancer cells will fail to undergo apoptosis and cell cycle arrest (Mader et al., 
1998; Bunz et al., 1999; Borralho et al., 2007; Ng et al., 2014).  
 
In addition, the resistance of colorectal cancer cells towards 5-FU is also attributed 
to the increase dosage of 5-FU during treatment (Mader et al., 1998; Ng et al., 2014). 
Besides the resistance of cancer cells towards 5-FU, other major drawbacks of 5-FU are 
(i) adverse side effects; (ii) the dose-limiting toxicity of using this drug (Li et al., 2009); 
and (iii) its short half-life (Mader et al., 1998; Jin et al., 2002; Ng et al., 2014). 5-FU has 
a short half-life due to a rate-limiting step of 5-FU catabolism in normal and tumour cells 
in which dihydropyrimidine dehydrogenase (DPD)-mediated conversion of 5-FU to 
dihydrofluorouracil (DHFU). Up to 80% of administered 5-FU is broken down by DPD 
to DHFU in the liver causing it to have a short half-life (He et al., 2008; Zhang et al., 
2008). These side effects worsen the life quality of the patients and contributes to the 
patient's refusal to continue treatment (Delval & Klastersky, 2002; Viale & Yamamoto, 
2008; Li et al., 2009). 
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2.2 Cell Death 
2.2.1        Cell Cycle  
Cell cycle is a series of developmental stages that both normal and cancer cells go 
through, which plays an important role in forming new cells to replace injured or dead 
cells. During cell cycle, two identical cells will be reproduced. These two new identical 
cells produced can enter the cycle again and reproduce new cells again when needed.  
 
The five stages of cell cycle are G1 phase, S phase, G2 phase, M phase and G0 
phase (American Cancer Society, 2015). The cycle is shown as a circle as the cell 
reproduction happens recurrently starting from the G0 phase and ending at the M phase 
then circles back to the G0 phase (Figure 2.1). 
  
Figure 2.1: Progression through the five phases of the cell cycle, G1 (gap 1), S (DNA 
synthesis), G2 (gap 2) M (mitosis), and G0 (resting phase) (American Cancer Society, 
2015)  
G0 phase is the resting phase, in which in this phase the cell does not start to divide 
yet. When the cells at G0 phase receives signalling for cell division, the G1 phase starts. 
In the G1 phase also known as the first gap phase, the cell prepares for division and 
undergoes metabolic changes such as increasing its protein amount and growing bigger. 
 10 
Next, the single cell then moves to the S phase, where DNA synthesis occurs in the 
nucleus. In DNA synthesis process, chromosomes containing DNA are replicated so that 
both new cells formed will have matching DNA strands. It also grows centrosomes, a 
microtubule-organizing structure that helps separate DNA during M phase. The following 
phase is the second gap, G2 phase. During this phase, the cell prepares for mitosis by 
growing more, producing more proteins and organelles and reorganizes its contents. This 
phase ends when mitosis begins, also called the mitotic, M phase. In this phase the nuclear 
division occurs, followed by cytokinesis where the cell separates into two new cells. The 
cell will then circulate back to phase G1 to divide again or if the standard number of cell 
is maintained, the cell will move to G0 phase until signals are received to begin dividing 
again (Alberts et al., 2002) 
 
Since the process of cell division is strictly regulated, at the G1/S boundary, intra-
S, and G2/M transitions, there is a defence system called checkpoints to resist DNA 
damage and genotoxic insult (Zhou & Elledge, 2000; Hyun et al., 2012). If these cycle 
regulators are flawed or mutated and do not respond to any signals caused by DNA 
damage, tumour will develop (Park & Lee, 2003). The cells with damaged DNA and cells 
which do not successfully complete DNA repair must continue with cell cycle arrest and 
removed by apoptosis (Bury & Cross, 2003; Hyun et al., 2012; Weitzman & Wang, 2013).  
 
2.2.2        Apoptosis 
Apoptosis, also known as programmed cell death is a highly-regulated process of 
cell death in all normal cell where unwanted or abnormal cells are eliminated. Apoptosis 
is activated by normal cells if a damaged DNA is detected. Cells proceeds to remove itself 
from the population as damaged DNA can render a cell useless and even harmful to an 
organism (Letai, 2008). Any defects occur at any point along the apoptosis pathways will 
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lead to the malignant transformation of the affected cells, tumour metastasis and 
resistance to anti-cancer drugs (Wong, 2011). Apoptotic cells can be characterized by 
shrinkage of the cell, condensation and fragmentation of the nucleus, blebbing of the 
plasma membrane and the formation of apoptotic bodies (Figure 2.2) 
 
Figure 2.2: Ultrastructural changes in apoptosis (2–3) and necrosis (7–8). (1) shows the 
normal cell. Early apoptosis in (2) can be characterized by the condensation and 
margination of the nuclear chromatin, condensation of the cytoplasm and also 
convolution of nuclear and cell outlines. (3) shows at a later stage where the apoptotic 
bodies are formed when the nucleus fragments and swellings on the cell surface separates. 
(4) shows the apoptotic bodies being phagocytosed by nearby cells and (5-6) degraded 
within the lysosomes. (7) shows the necrosis process characterized by the irregular 
clumping of chromatin, distension of the organelles, and focal disruption of the 
membranes. (8) shows the subsequent breakdown of the membrane but the cells usually 
retain the overall shape until removed by mononuclear phagocytes. (Kerr et al., 1994) 
  
 Apoptosis mechanism is complex and involves many pathways.The mechanism 
of apoptosis has to be understood as it is vital and aids the understanding of disease 
development caused by disrupted apoptosis. There are two major pathways which will 
 12 
lead to the execution of apoptosis: (i) the extrinsic or death receptor pathway, and (ii) the 
intrinsic or also known as mitochondrial pathway  (Figure 2.3) (Wong, 2011). Caspase is 
a family of protease enzymes that playing crucial roles in apoptosis as they are the 
initiators and executioners in both of the apoptosis pathways. 
   
Figure 2.3: The intrinsic and extrinsic pathways of apoptosis (Wong, 2011) 
 
 Extrinsic pathway in apoptosis starts when death ligands bind to a death receptor 
(e.g. TNFR, FAS). The ligand for TNFR are TNF while for FAS is FasL (Hengartner, 
2000). Adapter proteins such as TNF receptor-associated death doman (TRADD) and 
FAS associated death domain (FADD) and caspase-8 are recruited and activated. The 
binding site for an adaptor protein and the ligand-receptor-adaptor protein complex 
known as the death-inducing-signalling complex (DISC) is formed when the death ligand 
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bind to the death receptor (O’Brien & Kirby, 2008) which then starts the formation and 
activation of pro-caspase 8. Apoptosis starts when activated caspase-8 (initiator caspase) 
cleave other downstream or executioner caspases (Karp, 2008). 
 
 The intrinsic pathway occurs within the cell. The stimuli that activates the 
apoptotic pathway comprises of genetic damage that is irreparable, oxidative stress that 
is severe, hypoxia and the extreme concentration of cystolic Ca2+ (Karp, 2008; Wong, 
2011). In intrinsic pathway, the anti-apoptotic proteins regulate apoptosis by blocking the 
release of cytochrome-c (hemeprotein that can initiate the activation of caspase), while 
the pro-apoptotic proteins act by promoting such release. The balance between the pro- 
and anti-apoptotic proteins determines whether apoptosis would be initiated.  
 
 Other apoptotic factors that are released from the mitochondrial intermembrane 
space into the cytoplasm include apoptosis inducing factor (AIF), direct IAP binding 
protein with low pI (Diablo), second mitochondria-derived activator of caspase (Smac) 
and Omi/high temperature requirement protein A (HtrA2). Upon receiving the stress 
signals, Bcl-2 family protein are activated and subsequently interact with and inactivate 
the anti-apoptotic Bcl-2 proteins. The interaction results in the increase in membrane 
permeability and the release of pro-apoptotic molecules such as cytochrome-c into the 
cytoplasm (Danial, 2004; Wong; 2011). The cytoplasmic release of cytochrome-c 
activates caspase-3 via the formation of a complex known as apoptosome, which is made 
up of cytochrome-c Apaf-1 and caspase-9 (LaCasse et al., 2009; Wong, 2011). 
Smac/Diablo or Omi/HtrA2 promotes caspase activation by binding to inhibitor of 
apoptosis proteins (IAPs) which then loads to the interaction disruption of IAPs with 
caspase-3 or -9. 
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2.2.3      Apoptosis and Cancer 
When too little apoptosis occurs, cancer will arise as the abnormal cells continue 
reproducing and evade death (Wong, 2011). There are several ways a cancerous cell can 
downregulate or hider apoptosis such as imbalance of the anti-apoptotic and pro-apoptotic 
proteins, disability of death receptor signalling and reduced caspase function (Wong, 
2011).  Table 2.1 summarized on the ways apoptosis is reduced and the impacts caused 
by the reduction. 
Table 2.1: The ways apoptosis is reduced and the impacts caused by the reduction 
(Wong, 2011) 
Means of reducing 
apoptosis 
Impact of impaired apoptosis References 
 
Disrupted balance 
of pro- and anti-
apoptotic proteins 
 
 
Over expression of Bcl-2 family causes 
prostate cancer cells to evade apoptosis. 
 
Resistance of CRC to anti-cancer 
treatments is due to impaired apoptosis 
resulting from bax(G)8 frameshift 
mutation. 
 
Abnormal p53 expressed in melanoma 
cells causes the continuous propagation 
of this cell. 
 
Abnormal expression of Inhibitor of 
Apoptosis Protein (IAPs) causes 
pancreatic cancer cells to become 
resistant to treatment. 
 
 
(Raffo et al., 1995; 
Wong, 2011) 
 
(Miquel et al., 
2005; Wong, 2011) 
 
 
 
(Avery-Kiejda et 
al., 2011; Wong, 
2011) 
 
(Lopes et al., 2007; 
Wong, 2011) 
 
 
Reduced caspase 
function 
 
 
 
 
Patients suffering from stage II colorectal 
cancer have been found to have a 
downregulation of caspase-9 activity. 
 
Pathogenesis of choriocarcinoma has 
been found to be caused by the 
downregulation of both caspase-8 and -
10. 
 
 
(Shen et al., 2010; 
Wong, 2011) 
 
 
 
(Fong et al., 2006; 
Wong, 2011) 
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Table 2.1, continued 
Means of reducing 
apoptosis 
Impact of impaired 
apoptosis 
References 
 
Impaired death receptor 
signalling 
 
 
Leukaemia that is resistant 
to treatment have been 
found to be caused by the 
reduced expression of 
CD95, a death receptor 
signal. 
 
 
(Friesen et al., 1997; 
Wong, 2011) 
 
However, researchers have also found that apoptosis process plays important role 
in cancer treatment. New strategies have been developed to restore abnormal apoptotic 
pathway and stop the proliferation of cancer cells. Several ways cancer can be treated is 
by targeting the apoptosis factors including Bcl-2 family of proteins, p53, the IAPs, and 
caspases. Table 2.2 summarized on the apoptosis-based treatment strategy in cancer 
therapy. 
Table 2.2 Summary on the apoptosis-based treatment strategy in cancer therapy 
(Wong, 2011) 
Treatment 
strategies 
 
Summary of 
treatment strategy 
Example References 
 
Targeting 
the Bcl-2 
family of 
proteins 
 
Inhibiting anti-
apoptotic proteins 
by therapeutic 
agents 
 
 
Usage of oblimersen sodium 
when combined with 
conventional anti-cancer drugs 
showed chemosensitizing effects 
in chronic myeloid leukaemia 
patients. 
  
 
(Rai et al., 
2008; 
AbouNassar 
and Brown, 
2010; Wong, 
2011) 
 
 
Targeting 
p53 
 
Gene therapy 
 
 
Tumour cells of head and neck, 
prostate cancer and glioma and 
colorectal cancer are sensitized to 
ionizing radiation when wild type 
p53 gene is introduced . 
 
 
(Chène, 
2001; Wong, 
2011) 
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Table 2.2, continued 
 
Treatment 
strategies 
 
Summary of 
treatment strategy 
Example References 
 
Targeting 
caspases 
 
Caspase-based drug 
therapy 
 
By lowering the activation 
threshold of caspase, small 
molecules caspase activators have 
been reported to increase the 
sensitivity of cancer cells towards 
drugs. 
 
 
(Philchenkov 
et al, 2004, 
Wong, 2011) 
 
2.3 Drug Combination Strategy in Cancer Treatment 
   For decades, the standard treatment for most cancers are by drug combination 
strategy (Chou, 2006). Besides cancer, this strategy is also applied in the treatment of other 
diseases such as malaria, hypertension and other infectious diseases (Wagner, 2011). 
Combination chemotherapy is a growing interest among researchers (Pinto et al., 2011). 
One of the main reasons combination chemotherapy is applied is to use drugs that work 
by different mechanisms, thus reducing the probability of cancer cells developing 
resistency towards the drugs (Chabner et al., 2017). Each drug can also be used at its 
optimal dose without undesireable side effects when drugs with different effects are 
combined (Chabner et al., 2017). Combining anticancer drugs is also intended to 
maximize the efficacy of the drugs while minimizing the systemic toxicity through the 
delivery of lower drug doses (Pinto et al., 2011). Throughout the development of 
combination chemotherapy, the essential principles have remained largely unchanged. 
According to Pinto et al. (2011), the general principles of combination chemotherapy 
have been to: i) in order for a drug to be administered at a near-maximal dose, drugs with 
non-overlapping toxicities are used; ii) agents with dissimilar mechanisms of action and 
minimal cross-resistance are combined in order to hinder the development of broad 
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spectrum drug resistance; iii) single drugs with proven activity are favourably used; iv) 
combination  is administered at early stage of the  disease and at a schedule with a minimal 
treatment-free period between cycles but still allowing the recovery of sensitive target 
tissues.  Combination chemotherapy has been attributed to improve the compliance of 
patients due to the number of drug administrations being reduced, capability to overcome 
or delay MDR, the emergence of additive or synergistic interaction effects, and the 
reduction of drug concentration with subsequent diminishing of toxicity to healthy tissues 
(Pinto et al., 2011). 
 
2.4 Plant Natural Products 
Plants have been used for thousands of years to treat illnesses, health disorders 
and also to prevent diseases. The information of their therapeutic properties has been 
conveyed over the centuries within and among societies. In the early 1900s, before 
synthetic drugs were being widely used as medicine, 80% of all remedies were obtained 
from leaves, root and barks of plants (McChesney et al., 2007). Nowadays, plant-derived 
natural products have been used significantly to formulate drugs and therapeutic agents 
as approximately 60% of anti-cancer drugs and 75% of drugs for infectious diseases are 
either derived from natural products or are natural product derivatives (McChesney et al., 
2007). 
 
In contrast to plant’s primary metabolites (phytosterols, acyl lipids, amino acids, 
and nucleotides), plants secondary metabolites do not participate directly in the growth 
and development of plants (Harborne, 1993) and are unique among other taxonomic 
groups of the Plant Kingdom (Croteau, 2000). Plant natural products can be divided into 
three major groups based on their biosynthetic origins, which are the terpenoids, alkaloids 
and the allied phenolic compounds (Bourgaud et al., 2001). 
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The growing curiosity in plant natural products was due to their great 
conveniences as polymers, dyes, fibers, oils, waxes, glues, perfumes, drugs and also 
flavouring agents (Croteau, 2000). The secondary metabolites of plants were also found 
to have an exceptional supply of new medical coumpunds (Nirmala et al., 2011) and have 
a better patient tolerance and acceptance (Veeresham, 2012). This has fuelled the search 
for new drugs, herbicides, antibiotics and insecticedes and hopefully would find cures to 
various diseases. Morphine from opium plant was the first pure natural product that were 
used as medicine (Veeresham, 2012). Since then, more drugs are being discovered and 
formulated based on plant’s natural product and some are even widely used till this day 
and age. Table 2.3 summarized on some of plant-derived therapeutics agents and their 
application. The discovery of natural products have played a crucial part in human health 
due to their safety and efficacy.  
Table 2.3 Plant-derived therapeutic agents and their applications (Veerasham, 2012) 
Compound Plant Species Therapeutic Application 
 
Paclitaxel 
 
Taxus brevifolia 
 
Treatment of lung, ovarian and breast 
cancer. 
 
 
Artemisinin 
 
Artemisia annua 
 
Treatment of multidrug resistant 
malaria 
 
 
Silymarin 
 
Silybum marianum 
 
Treatment of liver diseases 
 
 
Nitisinone 
 
Callistemon citrinus 
 
Treatment of antityrosinaemia 
 
 
Galantamine 
 
Galanthus nivalis 
 
Treatment of Alzheimer’s disease 
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Table 2.3, continued  
 
Compound Plant Species Therapeutic Application 
 
Tiotropium 
 
Atropa belladonna 
 
Treatment of chronic obstructive 
pulmonary disease 
 
 
Dronabinol and 
Cannabidiol 
 
 
Cannabis sativa 
 
As pain relievers 
 
Capsaicin 
 
Capsicum annuum 
 
As pain relievers 
 
 
2.4.1 Plant as Anti-Cancer Agents 
  In 1950, the search for anti-cancer agents derived from plants began with the 
discovery and development of vinca alkaloids isolated from the Madagascar periwinkle 
(Catharanthus roseus synonym Vinca rosea) and the isolation of cytotoxic 
podophyllotoxins from Podophyllum species (Cragg & Newman, 2005). Some anti-
cancer agents isolated from plants that are currently being used all over the wolrd are 
taxol, vinblastine, topotecan, irinotecan, derivatives of comptothecin and etoposide 
derived from epipodophyllotoxin. Table 2.4 summarizes on anti-cancer agents isolated 
from plants. Higher plants that were selected as candidates in drug development must 
have the greatest probability of success. Researchers usually depends on the 
ethnomedicine information to explore its effectiveness prior development of drugs 
(Manju et al., 2012). 
Table 2.4: Anti-cancer agents isolated from  plants and their therapeutic applications 
(Manju et al., 2012). 
 
Compound Plant Species Therapeutic Application References 
 
Vincristine and 
Vinblastine 
 
Catharanthus 
roseus 
 
Treatment of leukaemias, 
lymphomas, advanced 
testicular cancer, breast and 
lung cancers, Karposi’s 
sarcoma 
 
(Cragg & 
Newman, 
2005) 
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Table 2.4, continued 
 
Compound Plant Species Therapeutic Application References 
 
Topotecan and 
Irinotecan 
 
 
Camptotheca 
acuminate 
 
Treatmenr of ovarian and 
small cell lung cancers and 
colorectal cancers 
 
 
(Creemers 
et al. 1996; 
Bertino, 
1997)  
 
Epipodophyllotoxin 
 
Podophyllum 
peltatum and 
Podophyllum 
emodi 
 
 
Treatment of lymphomas, and 
bronchial and testicular cancer 
 
(Harvey, 
1999) 
 
Homoharringtonine 
 
Cephalotaxus 
harringtonia 
 
Treatment of acute 
myelogenous leukaemia and 
chronic myelogenous 
leukaemia 
 
 
(Cragg & 
Newman, 
2005) 
 
Combretastatins 
 
Combretum 
caffrum 
 
Treatment of colon and lung 
cancers and leukaemia 
 
 
(Itokawa & 
Wang, 
2005) 
 
Elliptinium  
 
Bleekeria 
vitensis A. C. 
Sm. 
 
Treatment of breast cancer 
 
(Cragg & 
Newman, 
2005) 
 
 
2.4.2 Phyllanthus 
Phyllanthus species belongs to the family Phyllanthaceae and is the largest genus 
in the family. The Phyllanthaceae family consists of about 2,000 species with 60 genera 
(Samuel et al., 2005).  Phyllanthus species are mostly shrubs, herbs and trees (Burkill, 
1966; Ramasamy, 2012) and usually found in most tropical and subtropical countries 
(Eweka & Enogieru, 2011). The growth forms of Phyllanthus species are very diverse, 
including annual and perennial herbaceous, climbing, aborescent, and phyllocladous 
(Jagessar et al., 2008). 
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In traditional medicine, Phyllanthus have been used as medication to chronic liver 
disease (Liu et al., 2003). Phyllanthus has also been used in Ayurvedic medicine to treat 
gnorrhea, dysentery, jaundice, frequent menstruation, diabetes, skin swellings, ulcers, 
sores and also itchiness (Tang et al., 2013). In addition, in Traditional Chinese Medicine, 
Phyllanthus has been used  for the treatment of kidney stones and gallstones (Tang et al., 
2014). In addition, studies shows that extracts of Phyllanthus contain several valuable 
pharmacological effects, including antiviral activity against hepatitis B, antidiabetic, 
antibacterial, antihepatotoxic activities (Ramadasan & Harikumar, 2011; Dhongade & 
Chandewar, 2014; Tang et al., 2014) and also anti-cancer properties against different 
cancer cell lines of different origins (Lee et al., 2011; Tang et al., 2014). Some of the 
bioactive compounds reported in Phyllanthus species are geraniin, rutin, gallic acid and 
quercetin (Tang et al., 2014).   
 
2.4.3 Phyllanthus watsonii Airy Shaw 
Belonging to the family Phyllanthaceace, Phyllanthus watsonii Airy Shaw is an 
endemic species to Peninsular Malaysia and only found grown at the riverside of the 
Endau river of Endau Rompin, Johor (Ramasamy et al., 2012).  P. watsonii  is consumed 
as a tonic by the native people of Jakun of Kampung Peta, Endau Rompin (oral 
communication). P. watsonii was selected in this present study based on the previous 
reported work that shows the extracts of P. watsonii selectively inhibiting the growth of 
colon HT-29 cells via apoptosis and cell cycle modulation (Ramasamy et al., 2012).  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Plant Materials 
Leaves of Phyllanthus watsonii were collected from Endau Rompin National 
Park, Johor (Peninsular Malaysia). The authentication of the plant species was performed 
by Dr Sugumaran Manickam from Rimba Ilmu Botanical Garden, Institute of Biological 
Sciences, University of Malaya. The voucher specimen (Reference no. KLU46048) was 
deposited at the herbarium of Rimba Ilmu Botanical Garden, Institute of Biological 
Sciences, University of Malaya. 
 
Figure 3.1 : Phyllanthus watsonii Airy Shaw (Ramasamy et al., 2012) 
 
3.2 Preparation of P. watsonii Ethyl Acetate Extract 
Organic solvents with analytical grade were used for extraction and fractionation 
process of the plant sample. The organic solvents such as hexane, ethyl acetate and 
methanol were purchased from Fisher Scientific, UK. The leaves of P. watsonii (PW) 
were cleaned, sliced, dried, grounded, and extracted three times with methanol (Fisher 
Scientific, UK) at room temperature for 72 h. The solvent-containing extract was filtered 
with Whatman No.1 filter paper (Whatman, England) and the excess solvent was 
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evaporated under reduced pressure using a rotary evaporator (Buchi, Switzerland) 
resulting in a dark-greenish methanol extract. The extract was then further shaken 
vigorously with hexane (Fisher Scientific, UK) also until it appeared almost colourless. 
The chemical compounds that are soluble in hexane were filtered and pooled, followed 
by concentration under reduced pressure by rotary evaporator to yield hexane extract. 
Then, the remaining hexane insoluble compound was subjected to solvent-solvent 
extraction with a mixture of ethyl acetate (Fisher Scientific, UK) and distilled water in a 
ratio of 1 : 1 followed by vigorous mixing. This mixture was then successively 
fractionated using a separating funnel in which two distinct layers were formed. The 
bottom layer (water layer), where the residual water gathered was discarded while the 
ethyl acetate phase (top layer) was released into a clean beaker. The resultant filtrate was 
then concentrated under reduced pressure using a rotary evaporator to yield ethyl acetate 
extract (PW-E) which was used in the bioassay test. For the bioassay test, the PW-E was 
dissolved in dimethylsulfoxide (DMSO) (Sigma) as a stock solution with a concentration 
of 20 mg/ml before being further further diluted in 10 % DMSO. Figure 3.2 shows the 
schematic diagram of the extraction preparation procedure. 
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Fresh leaves were cleaned, sliced, dried and grounded into fine powder 
 
   
Methanol extract (dark greenish) 
 
 
Hexane insoluble compound 
 
 
 
 
 
Figure 3.2: Schematic Diagram of Extraction Procedure 
 
 
 
 
Extracted with methanol for 72h 
and concentrated under reduced 
pressure using a rotary evaporator 
Further shaken vigorously with hexane until it 
appeared almost colourless-the hexane 
soluble compound. The residue at the bottom-
contained hexane insoluble compound. 
Solvent-solvent extraction (v/v) 
ethyl actetate : water (1:1) 
   Ethyl acetate extract Water extract 
(1:1) 
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3.3 Liquid-Chromatography Mass Spectrometry (LC-MS / MS) Analysis  
 To determine the phytochemical compounds present in PW-E, the extract were 
analysed using a AB Sciex 3200Q Trap LC-MS/MS system with a spectrophotometer and 
an Ultra-high performance liquid chromatography (UHPLC) system (Perkin Elmer 
FX15) installed according to the method described by Ramasamy et al., (2012) with slight 
modifications. The chromatographic separation were performed on a column eluted with 
a mobile phase consisting of water (A) and acetonitrile (B) containing 0.1 % formic acid 
and 5 mM ammonium formate. A gradient elution of different concentration of A and B 
was used to separate the compounds of interest before the mass spectral analysis. The 
mass spectrometer analysis were performed in a positive ion mode for the detection of 
secondary compounds. Identities of the compounds were obtained by matching their 
molecular ions with reference standards and also by correlation with previoud published 
data on the chemical compounds of P. watsonii. 
 
3.4 Preparation of Culture Media and Other Solutions 
McCoy’s 5A powder and Minimum Essential Medium (MEM) powder and Foetal 
Bovine Serum (FBS) were purchased from Sigma-Aldrich, USA. Penicillin-streptomycin 
(100×) and amphotericin B (250 µg/ml) were obtained from PAA Lab, Austria. Accutase 
in DPBS, 0.5 mM EDTA was purchased from iCT, CA. N-2-Hydroxylethyl-Piperazine-
N-2-Ethane-Sulfonic acid (HEPES) was purchased from Molekula, UK. Neutral Red was 
purchased from ICN, Ohio. All other chemicals and solvents used were of the highest 
purity and grade available purchased from BDH AnalaR, UK and Sigma-Aldrich, USA. 
Cell culture plastic ware was from Nunc (Denmark) and 96-well culture plates were 
purchased from Orange Scientific (Belgium). 
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3.4.1 Basic McCoy’s 5A Medium 
 A bottle of McCoy’s 5A powder (Sigma-Aldrich, USA), was mixed with 1 L of 
sterile distilled water. Then, 0.2603 g of N-2-Hydroxylethyl-Peperazine-N-2-Ethane-
Sulfonic acid (HEPES) (Molekula, UK) and  2 g of sodium bicarbonate (NaHCO3, R & 
M Chemicals, UK) were added to the mixture. The pH of the medium was then adjusted 
to 7.4 using pH meter (Thermo Scientific) and then sterilized by filtration using 0.22 µm 
filter membranes (Orange Scientific). The sterilized medium was then stored in a sterile 
bottle at 4 °C for up to 4 months. 
 
3.4.2 10 % Supplemented McCoys Medium 
 90 ml of the prepared basic McCoy’s 5A (Sigma-Aldrich, USA) media were 
mixed with 10 ml of inactivated FBS (Sigma-Aldrich, USA) to produce 100 ml of 10% 
supplemented McCoy’s 5A (Sigma-Aldrich, USA) medium. The medium was then 
sterilized by filtration using a 0.22 µm filter membrane (Orange Scientific) and stored at 
4 °C for up to two weeks. 
 
3.4.3 Phosphate Buffered Saline (PBS) pH 7.4 
 1.52 g of sodium phosphate anhydrous (NaH2PO4, Merck), 0.58 g of potassium 
dihydrogen phosphate (KH2PO4, R & M Chemicals) and 8.4 g of sodium chloride (NaCl, 
R & M Chemicals) were mixed with 1 L of distilled water in the preparation of PBS. The 
pH of the PBS was then adjusted to 7.4 and then sterilized by filtration using 0.22 µm 
filter membrane (Orange Scientific). The PBS was then further sterilized by autoclave at 
112 °C. 
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3.4.4 0.4 % Tryphan Blue Solution 
 0.2 g of tryphan blue powder (Sigma-Aldrich, USA) was dissolved with 50 ml of 
distilled water in the preparation of 0.4 % tryphan blue solution. 
 
3.4.5 Neutral Red Stock Solution 
 Neutral Red  stock solution was prepared by dissolving 0.4 g of Neutral Red dye 
(R & M Chemicals) in 100 ml distilled water and then stored at 4 ° C. 
 
3.4.6 Neutral Red Medium 
Neutral Red   medium was prepared by diluting the Neutral Red  stock solution  
stock solution with 10 % supplemented McCoy’s 5A (Sigma-Aldrich, USA) medium at 
a ratio of 1:80 to produce a final concentration of 50 µg/ml.  The prepared Neutral Red 
medium was incubated overnight in the dark at room temperature and then centrifuged 
twice at 1,500 rpm for 10 min (Kubota 2010, Tokyo) prior to usage to remove any fine 
and needle-like precipitate of dye crystals. 
 
3.4.7  Neutral Red Washing Solution 
 Neutral Red  washing solution was prepared by dissolving 1 g of calcium chloride 
(CaCl, Systerm) in 99.5 ml of distilled water and 500 ml of formaldehyde (R & M 
Chemicals). The prepared solution was stored at 4 °C.  
 
3.4.8 Neutral Red Resorb Solution 
 Neutral Red resorb solution was prepared by mixing 50 ml of absolute ethanol 
(Fisher Scientific, UK) with 1 ml of acetic acid (Fisher Scientific, UK) and 49 ml of 
distilled water and then kept at 4 °C.  
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3.5 Cell Lines 
 The human colorectal carcinoma HCT-116 and human colorectal adenocarcinoma 
HT-29 cancer cell lines and human normal MRC-5 lung fibroblast cells were purchased 
from American Type Culture Collection (ATCC, USA). The colorectal cancer cells were 
cultured in 10 % supplemented McCoy’s medium while the normal lung fibroblast cell 
was cultured in MEM supplemented with 10 % (v/v) FBS. The cells were maintained in 
25 cm3 flasks with 10 ml media and then incubated at 37 °C in an incubator with 5 % CO2 
in a humidified atmosphere. The cells were subcultured every 2 – 3 days and routinely 
checked under an inverted microscope for any contamination.  
 
The HCT-116 cell line is derived from poorly differentiated (lack of gland-like 
structure or normal specialized structure) colorectal carcinoma wih Duke’s D stage while 
HT-29 cell line is derived from Duke’s stage C colorectal adenocarcinoma (Ahmed et al., 
2013). HCT-116 cell line has high clonogenicity and lack of differentiation capacity 
(Yeung et al., 2010). It is mainly used to study transfection and development of isogenic 
cell lines (pair of cell lines with similar genetic background except one targeted gene 
which is altered by knock-in or knock-out techniques which can lead to insights on the 
function of a specific gene (Teoh, 2016). Being able to adapt and resist against the 
cytotoxicity of 5-FU through the activation of survival autophagy and the lack of wild-
type p53, HT-29 cell line can act as a model for 5-FU resistance in researches (Sui et al., 
2014).  
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3.6 Neutral Red Uptake (NRU) Cytotoxicity Assay 
 The NRU cytotoxicity assay was modified based on the initial protocol described 
by Borenfreund & Puerner (1984). The cytotoxicity of the extracts was measured by NRU 
assay which is based on the uptake and subsequent lysosomal accumulation of the 
supravital dye, neutral red in the viable and uninjured cells.  
 
Firstly, the cells were detached from the flask with 1.0 ml solution of accutase in 
3 ml phosphate buffer solution (PBS) pH 7.4. The cell pellet was then obtained by 
centrifugation at 1,000 rpm for 5 min and the density of the viable cells were counted by 
0.4 % of tryphan blue exclusion method using a haemocytometer. The cells were then 
seeded in 96-well micro titer plate, at a concentration of 30,000 cells/ml and then 
incubated in an incubator at 37 ºC for 3 h to allow the cells to adhere before addition of 
the test agents. The experiment consisted of four groups for each cell line: (i) negative 
controlled cells only (without addition of any test agents); (ii) positive control (cancer 
cells treated with different 5-FU concentrations selected based on the sensitivity of the 
colon cancer cells towards the exposure to 5-FU (concentration ranging from 1.0 to 100.0 
µg/ml for human colorectal adenocarcinoma HT-29 cell line and 0.1 to 10 µg/ml for 
human colorectal carcinoma HCT-116 cell line) ; (iii) cancer cells treated with PW-E 
(concentration range from 1.0 to 100.0 µg/ml); (iv) cancer cells treated with 5-FU/PW-E 
combination. Series of PW-E with concentrations which gave 10 % to 90 % cell growth 
inhibition were combined with different concentrations of 5-FU for the combination index 
(CI) analysis. In this study, the concentration of PW-E/5-FU combination at ratio 3:1 
(constant combination ratio) based on the series of PW-E concentrations that give 10 % to 
90% cell growth inhibition were used for the study on HCT-116 cell line while for HT-29, 
non-constant combination ratio were used whereby the concentration of PW-E remains 
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constant at 0.03 µg/ml while the concentration of 5-FU were 30.0, 25.0, 19.0, 15.0 and 
10.0 µg/ml respectively. 
 
At the end of the incubation period, the medium was replaced with Neutral Red   
medium and incubated for further 3 h to allow for uptake of the vital dye into the 
lysosomes of viable and uninjured cells. The medium was then removed and cells were 
rapidly washed with the Neutral Red  washing solution. The dye within viable cells was 
then eluted from the cells with Neutral Red  Resorb solution and incubated for 1 min at 
room temperature with the plates agitated on a micro titer plate shaker for 30 min and 
then optical density (OD) against a blank reference was measured at 540 nm using  
Multiskan Go micro-plate reader (Thermo Fisher Scientific, USA). The experiments were 
done in three independent experiments for each of the test agents. The percentage of both 
HCT-116 and HT-29 cell inhibition were calculated according to the following formula.  
 
                    Absorbance of negative control – absorbance of treated cells 
% of inhibition:                                                                                                            x 100 
                                                             Absorbance of neative control 
 
3.7  Cytotoxicity (IC50) Analysis  
 
In the present study, the cytotoxic activities of P. watsonii ethyl acetate extract,  
PW-E  and chemotherapeutic drug, 5-Fluorouracil (5-FU) were screened by Neutral Red 
Uptake (NRU) assay against human colon HCT-116 cancer cell line; and human fetal 
lung fibroblast MRC-5 cell line. PW-E was tested at concentrations ranging from 0.1 – 
10 µg/ml towards HCT-116 cell line, and 1 – 100 µg/ml towards MRC-5 cell line. 5-FU 
were tested at concentrations ranging from 0.1 – 10 µg/ml towards HCT-116 cell line, 
and 10 – 1000 µg/ml towards MRC-5 cell line.  
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A complete dose-response curve and the IC50 value  were obtained by Compusyn 
1.0 Software. IC50 value refers to the concentration of extract or drug needed to inhibit  
50 % of cell growth. The negative control consisted of the cells without addition of  any 
drug or extract or drug and extract combination. The cytotoxicity data obtained were 
expressed as percentage of inhibition on the growth of HCT-116 cell line relative to 
negative control.  
 
The percentage of inhibitions were then converted to effect level, Fa value (0－1.0) 
before being calculated by CompuSyn 1.0 software (Chou & Martin, 2007) for further 
analysis. The potency, Dm (IC50, μg/ml) values (concentration required to inhibit cells 
viability by 50% as compared to the negative control) for PW-E were obtained from antilog 
of x-intercept of the median-effect plot generated by CompuSyn 1.0 computerized simulation. 
Based on the US National Cancer Institute guidelines, a crude extract is generally considered 
to have in vitro cytotoxic activity if the IC50 value in carcinoma cells, following incubation 
between 48 and 72 hours, is ≤ 20 μg/ml, while for a pure compound the IC50 value is ≤ 4 
μg/ml (Boik, 2001). 
 
3.8 Combination Index (CI) Analysis 
 The drug combination effect and other related analysis were determined by the 
Chou and Talalay equation (Chou, 2006): Combination Index, CI = (dA/DA) + (dB/DB). 
dA and dB are the doses of individual drugs alone, i.e., the concentration of 5-FU or PW-
E, respectively, that gives 50 % inhibition. DA and DB are the doses of 5-FU and PW-E 
in combination that inhibits 50 % of cell growth. CI > 1, CI = 1, and CI < 1 indicate 
antagonistic, additive, and synergistic effects, respectively.  
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3.9 Sensitization Factor 
The sensitization factor of the drug (5-FU) towards colorectal cancer cells        
HCT-116 and HT-29 by the PW-E extract was calculated as the ratio of IC50 drug alone / 
IC50 drug + PW-E extract.  
 
3.10 Selectivity Index Analysis 
The selectivity index (SI) was determined by the ratio between IC50 value of the 
extract on normal lung fibroblast MRC-5 cell and IC50 value of the extract on human 
colorectal carcinoma HCT-116 and human colon adenocarcinoma HT-29 cell. Extract with 
SI value greater than 3 were considered to have a high selectivity towards cancerous cells 
(Bézivin et al.,2003). 
 
3.11  Apoptosis Study  
3.11.1  Acridine Orange / Ethidium Bromide (AO/EB) Double Staining Assay 
The morphological changes of cells treated with PW-E, 5-FU and PW-E/5-FU 
combination were assessed using the Acridine Orange (AO, Sigma Aldrich, USA) / 
Ethidium Bromide, (EB, Sigma Aldrich, USA) double staining technique as previously 
described by Ribble et al. In two different assay, both HCT-116 and HT-29 cells were 
seeded at a concentration of 30,000 cells per well in a six-well plate and incubated for    
24 h at 37 °C before treatment with the PW-E, 5-FU and PW-E/5-FU combination at their 
respective IC50 values.  After an incubation period of 72 h, the cells were detached and 
pelleted. The supernatant was removed and the cells were subsequently stained with the 
prepared dye mixture (25 μl cold PBS and 2 μl AO/EB dye mixed in a 1:1 ratio). The 
stained cell suspension was transferred onto a clean glass slide and covered with a 
coverslip. The morphological changes relative to the untreated control was observed 
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using the narrow blue excitation filter on Leica fluorescent microscope. The images were 
then photographed at 200 × magnification. 
 
3.11.2 Determination of Caspase-3 Activation 
Caspase-3 activity were determined by using the Caspase-3 DEVD-R110 
Fluorometric and Colorimetric assay kit (Biotium, CA) according to the manufacturer’s 
protocol. The assay was based on a spectrophotometric detection of the chromophore, 
rhodamine 110 (R110), after its cleavage from the labelled substrate (Ac-DEVD) 2-R110. 
All experiments were carried out in three independent experiments. After treatment with 
10 µg/ml of PW-E, 5-FU and PW-E/5-FU combination for 48 h,  2 × 106 cells were 
pelleted and lysed with 50 µl of chilled cell lyses buffer and incubated on ice for 20 min. 
After incubation, cell suspension was centrifuged for 5 minutes at 12,000 g in 4 °C (Thermo 
Fisher Scientific, USA) to pellet insoluble cell debris. The supernatant (cytosolic extract) 
was then transferred to a fresh tube and 50 μl of Assay Buffer was added followed by 
incubation on ice for 30 minutes. Then, 5 μl of Enzyme Substrate was added to each sample 
and mixed well before final incubation at 37 °C for 60 minutes. The formations of R110 in 
samples were measured with and ELISA (enzyme-linked immunosorbent assay) micro-plate 
reader at absorbance 495 nm. The activity of caspase-3 in treated cells were determined by 
comparing the results with controls (untreated cells) and presented as percentage.  
 
3.12 Statistical Analysis 
The quantitative data for cytotoxic assay study and caspase-3 activation 
determination assay were presented as mean ± standard deviation. The differences 
between control, PW-E and PW-E/5-FU combination on treated cells were evaluated by 
using the Student’s t-test. *p < 0.05 denotes a statistically significant. 
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CHAPTER 4: RESULTS 
 
4.1 Liquid Chromatography-Mass Spectrometry Analysis of Phyllanthus 
watsonii Ethyl Acetate Extract (PW-E)  
            Ethyl acetate extract of Phyllanthus watsonii, PW-E was analyzed by LC-
MS/MS system allowing the detection of major compound(s). The data obtained were 
compared with the previous published data of chemical constituents of P.watsonii. The 
LC-MS/MS profiles of compounds in PW-E were obtained using Agilent Zorbax C18 
column (150 mm × 4.6 mm × 5 µM) are shown in Figure 4.1. The spectrometric analysis 
and tentatively identified major compounds are listed in Table 4.1.  
 Referring to the full chromatogram of PW-E (Figure 4.1), the major peak with a 
retention time (Rt) of 8.46 min was identified as kaempferol rhamnoside (Appendix F) 
(MW (molecular weight) m/z (average olecular weight) at 447.1). Other identified 
compounds are quercetin (Appendix E), kaempferol glucoside (Appendix G), ellagic acid 
(Appendix K), hyperin (Appendix H), strictinin isomer (Appendix C), galloyl HHDP 
hexoside, strictinin (Appendix B) and gallic acid (Appendix J). In the analysed sample of 
PW-E, two compounds were found to have the same MW, which are strictinin and galloyl 
HHDP (Hexahydroxydiphenic acid) hexoside (Appendix I). Their MW is the same 
because strictinin is an isomer of galloyl HHDP hexosidase. An isomer is each of two or 
more compounds with the same formula but a different arrangement of atoms in the 
molecule and different properties. 
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Table 4.1: Identification of compounds in PW-E by using LC-MS/MS analysis 
Retention Time 
(Rt)(min) 
MW (m/z) Tentative ID Compounds* 
 
2.43 
 
169.0 
 
Gallic acid 
 
4.46 633.1 Strictinin 
 
4.85 634.1 Strictinin isomer 
 
5.14 633.1 Galloyl HHDP hexoside 
 
5.81 633.1     Strictinin isomer 
 
7.45 463.1 Hyperin 
 
7.50 301.0 Ellagic acid 
 
    8.0 447.1 Kaempferol glucoside 
 
8.46 431.1 Kaempferol rhamnoside 
 
   9.80 301.0 Quercetin 
 
*identification of the compounds were aided by comparison with reference standards where available and 
by correlation with previus literature reports;  PW-E: P. watsonii ethyl acetate extract; MW: molecular 
weight 
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Figure 4.1:  LC-MS/MS profiles of chemical compounds in P. watsonii ethyl acetate extract.
3
6
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4.2 Cytotoxic Effects of PW-E, 5-FU and PW-E/5-FU Combo Against Human 
Colon HCT-116 and HT-29 Cancer Cell Line 
   In the present study, the cytotoxic activities of P. watsonii ethyl acetate extract,  
PW-E  and chemotherapeutic drug, 5-Fluorouracil (5-FU) were screened by Neutral Red 
Uptake (NRU) assay against human colon HCT-116, HT-29 cancer cell line  and human 
fetal lung fibroblast MRC-5 cell line. Based on the work by Ramasamy et al. (2012), PW-
E was selected as a test agent as it was reported that PW-E was the best performer in 
cytotoxicity against colon cancer cells in comparison with PW-E in different solvent. The 
percentage of inhibition of the HCT-116 and HT-29 colon cancer  cells triggered by the 
test agent used in this study, which is 5-FU, in various concentration in three independent 
experiment were then entered into CompuSyn1.0 software and the Dm value expressed 
as IC50, μg/ml (cytotoxicity effect) was generated from the antilog of x-intercept of 
median-effect plot (Chou & Martin, 2007). A complete dose-response curve and the IC50 
value  were obtained by Compusyn 1.0 Software.  
 
4.2.1 Cytotoxic Activity against HCT-116 Cell Line 
   Cytotoxicity (IC50 value in µg/ml) of PW-E, 5-FU and PW-E/5-FU combination 
towards HCT-116 cells are summarized in Table 4.2. 
 
5-Fluorouracil (5-FU)   
   The concentration of  5-FU required to reduce HCT-116 cells viability by 50 % 
as compared to the negative control cells depicted as IC50 value was 1.588 ± 0.46 µg/ml. 
Based on the US National Cancer Institute guidelines, a crude extract is generally 
considered to have active cytotoxic activity if the IC50 value in carcinoma cells, following 
incubation between 48 and 72 hours, is ≤ 20 μg/ml, while ≤ 4 μg/ml for pure compounds. 
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Therefore, based on the result obtained, the chemotherapeutic drug 5-FU possessed 
cytotoxic activity against HCT-116 cancer cells.  
 
P. watsonii ethyl acetate extract (PW-E) 
Concentration of  PW-E required to reduce HCT-116 cells viability by 50 % as 
compared to the control cells depicted as IC50 value was 1.522 ± 0.16 µg/ml. Based on 
the US National Cancer Institute guidelines, PW-E possessed cytotoxic activity towards         
HCT-116 cancer cells.  
 
PW-E/5-FU Combination 
The concentration of  PW-E/5-FU  combination  at ratio 3:1 required to reduce 
HCT-116 cells viability by 50 % as compared to the control cells depicted as IC50 value 
was 1.482 ± 0.25 µg/ml. PW-E/5-FU combination inhibited 50 % of HCT-116 cells with 
lower concentration in comparison when the HCT-116 cells was treated with 5-FU and 
PW-E alone. 
Table 4.2: Cytotoxicity (IC50 , µg/ml) of 5-FU, PW-E and PW-E/5-FU combo 
against HCT-116 cell line 
Test Agent Cytotoxicity (IC50 , µg/ml) a on       
HCT-116b  
 
5-FUd 
 
 
1.588 ± 0.46 
 
 
PW-Ec 
 
 
1.522 ± 0.16 
 
PW-E/5-FUe 
 
 
1.482 ± 0.25 
aData are represented as mean±SD from three independent experiments, triplicate each; b colon cancer cells; 
c P. watsonii ethyl acetate extract; d5-Fluorouracil; ecombination at ratio 3:1. 
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Figure 4.2: Dose-effect curve for PW-E and 5-FU against human colon HCT-116 cancer 
cell line generated from Compusyn 1.0 software. PW-E: P. watsonii ethyl acetate extract; 
5-FU: 5-Fluorouracil; Fa: effect level (HCT-116 cells growth inhibition percentages/100). 
 
Figure 4.2 shows the dose-effect curve for PW-E and 5-FU against HCT-116 cell 
line. Dose-effect relationship shows the changes or effect that an organism goes through 
when exposed to a stressor after a certain amount of time. Based on the figure above, the 
effect that both 5-FU and PW-E exerted on the growth of HCT-116 cell line was almost 
similar, with PW-E exhibited slightly higher growth inhibiton of HCT-116 cells 
compared to 5-FU. 
 
4.2.2 Cytotoxic Activity against HT-29 Cell Line 
            Cytotoxicity (IC50 value in µg/ml) of the PW-E, 5-FU and PW-E/5-FU 
combination towards HT-29 cell are summarized in Table 4.3. 
 
 
Concentration of PW-E and 5-FU (µg/ml) 
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5-Fluorouracil (5-FU) 
The concentration of  5-FU required to reduce HT-29 cells viability by 50 % as 
compared to the negative control cells depicted as IC50 value was 19.70 ± 1.72 µg/ml. 
Based on the US National Cancer Institute guidelines the chemotherapeutic drug of 5-
FU does not possessed any cytotoxic activity towards HT-29 cancer cells, meaning that 
the anti-cancer drug is rather ineffective to inhibit the growth of the colon HT-29 cancer 
cells. 
 
P. watsonii Ethyl Acetate Extract (PW-E) 
   The concentration of  PW-E required to reduce HT-29 cells viability by 50 % as 
compared to the control cells depicted as IC50 value was  0.03 ± 0.003 µg/ml. Based on 
the US National Cancer Institute guidelines, PW-E has cytotoxic activity on HT-29 cancer 
cells.  
 
PW-E/5-FU Combination 
   The concentration of  PW-E/5-FU  combination  required to reduce HT-29 cells 
viability by 50 % as compared to the negative control cells depicted as IC50 values were        
0.03 µg/ml of PW-E and 10.0 µg/ml of 5-FU respectively. PW-E/5-FU combination 
inhibited 50 % of HT-29 cells with lower concentration of 5-FU compared to when the 
cells was treated with 5-FU and PW-E alone.  It can be observed that by combining PW-
E with 5-FU, the cytotoxicity effect of 5-FU was increased by 1.9-fold towards HT-29 
cells. 
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Table 4.3: Cytotoxicity (IC50 , µg/ml) of 5-FU, PW-E and PW-E/5-FU combo 
against HT-29 cell line 
Test Agents Cytotoxicity (IC50 , µg/ml) a on          
HT-29 cell lineb 
 
5-FUd 
 
 
19.70 ± 1.72 
 
PW-Ec 
 
 
0.03 ± 0.003 
 
PW-E/5-FUe 
 
 
0.03/10.0 
 
aData are represented as mean±SD from three independent experiments, triplicate each; b colon cancer cells; 
cP. watsonii ethyl acetate extract; d5-Fluorouracil; ecombination at PW-E/5-FU concentration of 0.03 and 
10.0 μg/ml. 
 
 
Figure 4.3:  Dose-effect curve for PW-E and 5-FU against human colon HT-29 cancer 
cell line generated from Compusyn 1.0 software. PW-E: P. watsonii ethyl acetate extract; 
5-FU: 5-Fluorouracil; Fa: effect level (HT-29 cells growth inhibition percentages/100). 
 
    Based on Figure 4.3, PW-E has a higher potency in cell inhibition  compared 
to 5-FU as it showed a very steep curve at the lower concentrations and PW-E inhibited 
higher percentages of the HT-29 cells at  much lower concentrations. 
Concentration of PW-E and 5-FU (µg/ml) 
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4.2.3 Combination Index Analysis on HCT-116 Cell Line 
    Combination Index (CI) analysis was performed in this study to further explore 
the effect of PW-E when combined with 5-Fluorouracil (5-FU) on both HCT-116 and 
HT-29 colon cancer cell lines. Combination Index (CI) analysis was performed and then 
the CI values, isobologram and Drug Reduction Index were subsequently generated by 
CompuSyn 1.0 software. According to Chou and Martin (2007), the combination between 
two drugs or agents can interact to either reduce or increase its inhibitory efficacy towards 
the tested cells thus producing three possible effects; (i) synergism, in which the 
combined effect is more than additive effect; (ii) additive, the combined effect predicted 
by the mass-action law principle in the absence of synergistic and antagonistic effect; and 
(iii) antagonism, the combine effect is lesser than additive effect. 
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Figure 4.4: Dose-effect curve for PW-E, 5-FU and PW-E/5-FU combination against 
human colon HCT-116 cancer cells generated from Compusyn 1.0 software. PW-E:         
P. watsonii ethyl acetate extract; 5-FU: 5-Fluorouracil; PW/5-FU: PW-E/5-FU combo; 
Fa: effect level (HCT-116 cells growth inhibition percentages/100). 
 
 
Figure 4.4 shows the dose-effect curve generated from Compusyn 1.0 Software. 
The cytotoxicity data from three independent experiment were entered into the software 
and the potency, Dm (IC50) and other analysis were summarized in Table 4.4.  
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Table 4.4: Dose-effect relationship of PW-E/5-FU combination on human colon HCT-116 cancer cell line 
Inhibitory 
Concentration at 72 
hours 
 
 
PW-Ea (µg/ml) 
 
5-FUb (µg/ml) 
 
PWE/5-FU (3:1) 
 
CIc 
 
Sfd 
 
IC50 
 
 
1.522 ± 0.16 
 
1.588 ± 0.46 
 
1.482 ± 0.25 
 
0.85982 
 
1.07 
IC75 5.823 ± 0.32 13.715 ± 0.69 4.497 ± 0.154 0.61017 3.05 
 
IC90 
 
22.273 ± 1.36  118.389 ± 1.12 13.024 ± 10.34 0.46592 9.09 
a P. watsonii ethyl acetate extract; b 5-Fluorouracil; c combination index which measure the degree of PW-E/5-FU interaction, CI was measured at the affected fractions of 50 
% (IC50), 70 % (IC70) and 90 % (IC90), CI < 1 indicate synergism interaction, CI > 1 indicate antagonism interaction and CI=1 indicate additive interaction.; dsensitization 
factor of the drug (5-FU) towards cancer cell (HCT-116) by extract (PW-E) was calculated as the ratio of IC50/75/90 drug alone/ IC50/75/90 drug + extract. 
  
 
 
4
4
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Constant ratio design with ratio of 3:1 was selected in combining both PW-E and 
5-FU. From the CI analysis, it shows that PW-E/5-FU combination exerted CI values of 
0.85982 at IC50, 0.61017 at IC75 and 0.46592 at IC90 when tested against HCT-116 cells. 
According to the guidelines given by Chou and Martin (2007), any combination with CI 
> 1, indicates antagonism interaction, CI = 1, additive interaction and CI < 1 indicate 
synergistic interaction between the two agents.This data indicate that combination of PW-
E and 5-FU able to interact synergistically (CI <1) to inhibit the growth of HCT-116 cells.  
 
The data in Table 4.4 above also summarized the sensitization factor (Sf) of 5-FU 
towards HCT-116 cell line by PW-E and was calculated as the ratio of IC50/75/90 of 
individual 5-FU and IC50/75/90 of PW-E/5-FU combination. Based on the data above, it 
can be seen clearly that there was an increase in Sf values at higher inhibitory 
concentration. This indicates that the presence of PW-E in PW-E5-FU combination has 
sensitizing effect in increasing the inhibitory activity of 5-FU towards HCT-116 cells. In 
short, the increase in sensitization factor at increasing inhibition concentration indicates 
that the PW-E extract further sensitizes the HCT-116 cell towards 5-FU. 
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Figure 4.5: Isobologram of Combination Index (CI) of PW-E/5-FU combo towards HCT-
116 cells. The lines from three independent replicates indicated the degree of interaction 
between PW-E and 5-FU. The horizontal line signify additive effect, CI=1. Combination 
points of PW-E/5-FU situated below and upper level of the line are synergistic and 
antagonistic respectively. PW-E:  P. watsonii ethyl acetate extract; 5-FU: 5-Fluorouracil; 
Fa: effect level (HCT-116 cells growth inhibition percentages/100).  
 
 
 Figure 4.5 depicts the combination effect of PW-E/5-FU at ratio 3:1 on HCT-116 
cells. The three lines represented three independent replicates of the combination study. 
The extract-drug combinations isobologram showcased six dose combinations inhibition 
for each replicate. The diagonal line indicates additive interaction (between the extract 
and drug, in which inhibitory effect that fall above each line are antagonism, while 
inhibitory effect that fall below are synergism. From Figure 4.5, most data points fell 
under the diagonal line, indicating that the PW-E/5-FU combination exerts synergistic 
interaction at higher concentration combination dosages at with Fa  > 0.5, while at certain 
low concentration combination, Fa < 0.6, antagonistic interaction can be seen. However, 
in cancer therapy, the low Fa value (effect level) is of less concern compared to high Fa 
value as killing cancer in a small fraction is not useful in cancer therapy (Zhang et al., 
2016).   
 
Antagonism 
Additive 
Synergism 
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Figure 4.6: Isobologram for PW-E/5-FU combination at ratio 3:1 against HCT-116 cell 
line. The lines indicated the degree of interaction between PW-E (Concentration A) and 
5-FU (Concentration B). Effect level that fall on the diagonal lines of its colour indicated 
additive, below the lines synergism and above the lines, antagonism interaction. PW-E: 
P. watsonii ethyl acetate extract; 5-FU: 5-Fluorouracil; Fa: effect level (HCT-116 cells 
growth inhibition percentages/100). 
  
 Figure 4.6 shows the isobologram of simultaneous and sequential exposure of 
HCT-16 cells to PW-E/5-FU combination at three cell inhibitory effect level of Fa, 50 % 
(Fa = 0.5), 70 % (Fa = 0.70) and 90 % (Fa = 90). The line indicates alignment of 
theoretical value of an additive interaction between concentration A (PW-E) and 
concentration B (5-FU). Values above the diagonal line of additive effects in the 
isobologram suggest antagonism and below line suggests synergism interaction. It can be 
seen that all the values fall below the diagonal line indicating that the PW-E/5-FU 
combination lead to synergism interaction upon treatment on HCT-116 cells. 
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Table 4.5: Drug Reduction Index (DRI) values for PW-E, 5-FU and PW-E/5-FU 
combo at ratio 3:1 against HCT-116 cells 
a Fa: Fractional inhibition; b Fa=0.500 is Compusyn computerized stimulation of the DRI at 50 % inhibition 
based on the IC50 of individual test agents; c P. watsonii ethyl acetate extract; d 5-Fluorouracil; e a measure 
on how many folds the dose of 5-FU in a synergistic combination with PW-E may be reduced at a given 
level when compared with the doses of each alone. DRI > 1 indicate dose reduction, DRI < 1 indicate not-
favourable reduction and DRI =1 indicates no dose reduction. 
 
Table 4.5 shows the Drug Reduction Index (DRI) data for each PW-E and 5-FU 
prior PW-E/5-FU combination at ratio of 3:1 against HCT-116 cells. The DRI for drug-
agent combination is  measured on how much (-fold) the dose of a drug or agent (e.g. 
PW-E or 5-FU) in synergistic combination may be reduced at a given effect level 
compared with the dose of each drug alone. The DRI is another mathematical 
interpretation of the CI, and CI= 1/(DRI)1 + 1(DRI)2. The value of DRI >1  shows that 
the combination is favourable in terms of clinical therapy (Chou, 2010). Based on Table 
4.5, it can be inferred that to achieve 50 % HCT-116 cells inhibition, it requires 1.522 
µg/ml of PW-E, and 1.588 µg/ml of 5-FU of each individual extract and drug. However, 
it requires 1.53452-fold less PW-E and 4.80342-fold less 5-FU to achieve the same 50 % 
inhibition if both the drug and extract when they are combined. 
 
Fa a 
Concentration (µg/ml) DRI e 
PW-E c 5-FUd PW-E c 5-FUd 
0.828 10.345 34.527 1.379        13.811 
0.825 10.138 33.425 2.253 22.283 
0.806 8.688 26.086 2.317 20.869 
0.601 2.508 3.543 1.337 5.669 
0.217 0.319 0.129 0.425 0.515 
0.106 0.112 0.024 0.300 0.193 
0.035 0.026 0.002 0.351 0.094 
0.500 b 1.522 1.588 1.534 4.803 
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Figure 4.7: Drug Reduction Index (Fa-DRI) plot for PW-E, 5-FU and PW-E/5-FU combo 
at 3:1 ratio on HCT-116 and HT-29 cell lines. DRI >1 indicated favourable dose reduction 
and the combination is favourable in terms of clinical therapy (Chou, 2010). PW-E: P. 
watsonii ethyl acetate extract; 5-FU: 5-Fluorouracil. Fa: effect level (HCT-116 cells 
growth inhibition percentages/100). 
 
 Figure 4.7 depicts the DRI for PW-E/5-FU combination at ratio of 3:1 on HCT-
116 cells. DRI > 1 indicate favourable dose reduction, DRI < 1 indicate not favourable 
reduction and DRI = 1 indicates no dose reduction (Chou, 2010). It can be seen in the 
graph most of the plots fall in a favourable dose reduction region (DRI > 1). 
 
4.2.4 Combination Index Analysis of HT-29 Cell Line 
   Drug combination analysis was determined by the Chou and Talalay equation 
(Chou, 2006): Combination Index, CI = (dA/DA) + (dB/DB). dA and dB are the doses of 
individual drugs alone, i.e., the concentration of 5-FU or PW-E, respectively, that gives 
50 % inhibition. According to the guidelines given by Chou and Martin, 2007, any 
combination with CI > 1, indicate antagonism interaction, CI = 1, additive interaction and 
CI < 1 indicate synergistic interaction between the two agents. 
Favourable 
Non-Favourable 
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Figure 4.8: Dose-effect curve for PW-E, 5-FU and PW-E/5-FU combination against 
human colon HT-29 cancer cells generated from Compusyn 1.0 software. A: Dose-Effect 
curve for 5-FU and PW-E tested alone against HT-29 cells; B: Dose-Effect curve for PW-
E and 5-FU combined tested against HT-29 cells. PW-E: P. watsonii ethyl acetate extract; 
5-FU: 5-Fluorouracil; PWC1, PWC2, PWC5: three independent experiments of PW-E 
tested alone against HT-29 cells; Fa: effect level (HT-29 cells growth inhibition 
percentages/100). 
 
B 
A 
Concentration  (µg/ml) 
Concentration  (µg/ml) 
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 Figure 4.8 shows the dose-effect curve generated from Compusyn 1.0 Software. 
(A) Dose-Effect curve for 5-FU and PW-E tested alone against HT-29 cells. (B) Dose-
Effect curve for PW-E and 5-FU combined tested against HT-29 cells. The cytotoxicity 
data from three independent experiment were entered into the software and the potency, 
Dm (IC50) and other analysis are summarized in Table 4.7.  
 
Table 4.6: Dose-effect relationship of PW-E/5-FU combination on human colon       
HT-29 cancer cell line 
 
 
Extract/Drug 
 
Dmc (µg/ml) 
 
Md 
 
re 
 
CI f 
PW-Ea 0.03 ± 0.003 0.22029 0.87789   
5-FUb 19.70 ±1.72 0.19469 0.95914   
PWE/5-FU 
(0.03:19.0) 
   0.67947  
a P. watsonii ethyl acetate extract; b 5-Fluorouracil; c median-effect dose that produces 50% cell death; d 
shape of dose-effect curve; e conformity parameter for goodness of fit, for in vitro experiment r > 0.95 are 
considered good;  f combination index which measure the degree of PW-E-/5-FU interaction, CI was 
measured at the affected fractions of 50 % (IC50), 70 % (IC70) and 90 % (IC90), CI < 1 indicate synergism 
interaction, CI > 1 indicate antagonism interaction and CI=1 indicate additive interaction. 
 
 
The concentrations to inhibit 50 % of HT-29 colon cancer cell by both 5-FU and 
PW-E were 19.70 ±1.72 µg/ml and 0.03 ± 0.003 µg/ml respectively and the concentration 
value was selected based on the IC50 values of the drug and extract. Non-constant ratio 
design was selected for this experiment and the ratio used was a constant 0.03 µg/ml for 
PW-E extract while the concentration of 5-FU used was 30.0, 25.0, 19.0, 15.0 and 10.0 
µg/ml respectively. The CI analysis shows that PW-E/5-FU combination exhibited IC50 
value of 10.0 µg ml of 5-FU with 0.03 µg/ml of PW-E when tested against HT-29 cells. 
This data indicated lower concentration of 5-FU is needed to be combined with PW-E in 
order to achieve 50 % inhibition of HT-29 cells.  
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Table 4.6 shows CI analysis for HT-29 cell line tested with the combination of     
5-FU and PW-E at a non-constant ratio where the concentration of PW-E was kept 
constant.  The CI analysis indicated that PW-E and 5-FU interacted synergistically as 
shown by CI < 1 in the Table 4.6. The sensitization factor for HT-29 cell line could not 
be calculated because since using non-constant combination ratio concept, the Compusyn 
1.0 software does not calculate the IC70 and IC90. 
 
 
Figure 4.9: Isobologram of Combination Index (CI) of PW-E/5-FU towards HT-29 cells. 
The lines indicated the degree of interaction between PW-E and 5-FU. Effect level that 
fall on the diagonal lines of its colour indicated additive, below the lines synergism and 
above the lines, antagonism interaction. PW-E: P. watsonii ethyl acetate extract; 5-FU: 
5-Fluorouracil; PWC1, PWC2, PWC5: three independent experiments of PW-E tested 
alone against HT-29 cells; Fa: effect level (HT-29 cells growth inhibition 
percentages/100). 
 
 Figure 4.9 depicts the combination effect of PW-E/5-FU at concentration of  0.03 
and 10.0 μg/ml for PW-E and 5-FU respectively on HT-29 cells. The three different 
colours of data points represented three independent replicates of the combination study. 
The extract-drug combinations isobologram, showcased five dose combinations 
Additive 
Antagonism 
Synergism 
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inhibition for each replicate. The combination ratio was at a constant 0.03 µg/ml for PW-
E while the concentrations of 5-FU are 30.0, 25.0, 19.0, 15.0 and 10.0 µg/ml respectively 
as non-constant ratio concept were used. The diagonal line indicated additive interaction 
between the extract and drug, in which inhibitory effect that fall above each line are 
antagonism, while inhibitory effect that fell below the diagonal line is synergism. From 
the figure, all data points fell under the diagonal line, indicating that the PW-E/5-FU 
combination exerts synergistic interaction at higher dosages. In cancer therapy, the low 
Fa value (effect level) is of less concern compared to high Fa value as killing cancer in a 
small fraction is not useful in cancer therapy (Zhang et al., 2016).   
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Figure 4.10: Isobologram for PW-E/5-FU combination at concentration of  0.03 and    
10.0 μg/ml concentration for PW-E and 5-FU respectively against HT-29 cell line. The 
lines indicated the degree of interaction between PW-E (Concentration A) and 5-FU 
(Concentration B). Effect level that fall on the diagonal line indicated additive, below the 
line synergism and above the line, antagonism interaction. PW-E: P. watsonii ethyl 
acetate extract; 5-FU: 5-Fluorouracil; Fa: effect level (HT-29 cells growth inhibition 
percentages/100); Point 1-5: The five different colours of data points represented fve 
independent replicates of the combination study. 
 
 Figure 4.10 shows the isobologram of simultaneous and sequential exposure of 
HT-29 cells to PW-E/5-FU combination at 50 % (Fa = 0.5), 70 % (Fa = 0.70) and 90% 
(Fa = 90) Fa. The line indicates alignment of theoretical value of an additive interaction 
between concentration A (PW-E) and concentration B (5-FU). The five different colours 
of data points represented five independent replicates of the combination study. Values 
above the diagonal line of additive effects in the isobol suggest antagonism and below 
line suggests synergism interaction. It can be seen that all the values fall below the 
diagonal line indicating that the PW-E/5-FU combination lead to synergism interaction 
upon treatment on HT-29 cells. 
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Table 4.7: Drug Reduction Index (DRI) values for PW-E, 5-FU and PW-E/5-FU 
combo (0.03:10.0) against HT-29 cells 
a Fa: Fractional inhibition; b Fa=0.500 is Compusyn computerized simulation of the DRI at 50 % inhibition 
based on the IC50 of individual test agents; c P. watsonii ethyl acetate extract; d 5-Fluorouracil; e a measure 
on how many folds the dose of 5-Fu in a synergistic combination with PW-E may be reduced at a given 
level when compared with the doses of each alone, DRI>1 indicates favorable dose reduction, DRI<1 
indicate not-favourable reduction and DRI = 1 no dose reduction (Chou, 2010). 
 
Table 4.7 shows the Drug Reduction Index (DRI) data for each PW-E and 5-FU 
prior PW-E/5-FU combination at concentration of 0.03 and 10.0 μg.ml against  HT-29 
cells. The DRI for drug-agent combination is measured on how much (-fold) the dose of 
a drug or agent (e.g. PW-E) in synergistic combination may be reduced at a given effect 
level compared with the dose of each drug alone. The DRI is another mathematical 
interpretation of the CI, and CI = 1/(DRI)1 + 1(DRI)2. The value of DRI > 1 shows that 
the combination is favourable in terms of clinical therapy (Chou, 2010).  
 Based on the Table 4.7, it can be inferred that to achieve 50 % inhibition HT-29 
cells inhibition, it requires 0.03 µg/ml of PW-E, and requires 19.0 µg/ml of 5-FU of each 
individual extract and drug. However, it requires 2.078-fold less PW-E and 4.080-fold 
less 5-FU to achieve the same 53 % inhibition if both the drug and extract were combined. 
 
Fa a 
Concentration (µg/ml) DRI e 
PW-E c 5-FUd PW-E c 5-FUd 
0.645      0.488      418.658      16.268      13.955       
0.623      0.316     256.508      10.551      10.260       
0.625      0.331      269.690      11.029      14.194       
0.609     0.243      190.358      8.1063      12.690       
0.536     0.062      40.8030      2.078      4.080      
      0.500 b   0.003 19.0000   
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Figure 4.11: Drug Reduction Index (Fa-DRI) plot for PW-E, 5-FU and PW-E/5-FU 
combo against HT29 cell line. DRI > 1 indicated favourable dose reduction and the 
combination is favourable in terms of clinical therapy (Chou, 2010). PW-E: P. watsonii 
ethyl acetate extract; 5-FU: 5-Fluorouracil; Fa: effect level (HT-29 cells growth inhibition 
percentages/100). 
  
 Figure 4.11 depicted the DRI for PW-E/5-FU combination at ratio of 0.03:10.0 on 
HT-29 cells. DRI > 1 indicates favourable dose reduction, DRI < 1 indicate not favourable 
reduction and DRI = 1 indicate no dose reductions. It can be seen from the graph that all 
of the plots fell in a favourable dose reduction region (DRI > 1). 
 
4.2.5 Selectivity Index Analysis of HCT-116 Cell Line 
   PW-E, 5-FU and PW-E/5-FU combo were further tested against human fetal lung 
MRC-5 fibroblast cells in order to determine the Selectivity Index (SI) and the analysis 
data were tabulated in Table 4.8. 
 
 
 
Favourable 
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Table 4.8: Cytotoxicity (IC50, µg/ml) of 5-FU, PW-E and PW-E/5-FU against 
HCT-116 Cell Line 
 
 
Cell lines 
b 
IC50 (µg/ml) a  
SI f 
PW-E c 5-FUd PW-E/5-FUe  
HCT-116 1.522 ± 0.16 1.588 ± 0.46 1.482 ± 0.25  
MRC-5 3.640 ± 0.14 1687.884 ± 958 103.64 69.932 
a Data are represented as mean ± SD from three independent experiments, triplicate each; b HCT-116 
(colorectal cancer) and MRC-5 (normal lung fibroblast); c P. watsonii ethyl acetate extract; d 5-Fluorouracil; 
e combination at ratio 3:1 for HCT-116 cell; f SI, selectivity index is the ratio of the IC50 values of 
extract/drug on MRC5 cells to HCT-116. Samples with SI greater than 3 were considered to have high 
selectivity towards the cancer cells (Mahavorasirikul et al., 2010).  
  
The SI values were determined by comparing the cytotoxic activity of  PW-E/5-
FU combo on normal human lung MRC-5 fibroblast cells to colon HCT-116 cancer cell 
line. According to Mahavorasirikul et al. (2010), if the SI value is more than 3, the combo 
is said to be highly selective towards the cancer cells. The SI values calculated for the 
extract-drug combo tested against MRC-5 showed that the combo was more selective 
towards the cancer cells compared to normal cells as the value was more than 3.
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4.2.6 Selectivity Index Analysis of HT-29 Cell Line 
          PW-E, 5-FU and PW-E/5-FU combo were further tested against human fetal 
lung MRC-5 fibroblast cells in order to determine the Selectivity Index (SI) and the 
analysis data were tabulated in Table 4.9. 
Table 4.9: Cytotoxicity (IC50, µg/ml) of 5-FU, PW-E and PW-E/5-FU against       
HT-29 cell line  
 
Cell lines b 
IC50 (µg/ml) a  
SI f 
PW-E c 5-FUd PW-E/5-
FUe 
HT-29 0.030 ± 
0.003 
19.000 ± 1.8 10.030  
10.33 
MRC-5 3.640 ± 
0.14 
1687.884 ± 
958 
103.64 
a Data are represented as mean ± SD from three independent experiments, triplicate each; b HT-29 
(colorectal cancer) and MRC5 (normal lung fibroblast); c P. watsonii ethyl acetate extract; d 5-Fluorouracil; 
e combination at IC50 of both PW-E and 5-FU against HT-29 cells which are 0.03 µg/ml and 19.0 µg/ml 
respectively. f SI, selectivity index is the ratio of the IC50 values of extract/drug on MRC-5 cells to HT-29. 
Samples with SI greater than 3 were considered to have high selectivity towards cancer  cells 
(Mahavorasirikul et al., 2010).  
  
The SI values were determined by comparing the cytotoxic activity of                   
PW-E/5-FU combo on normal human lung MRC-5 fibroblast cells to colon HT-29 cancer 
cell lines. According to Mahavorasirikul et al. (2010), if the SI value is more than 3, the 
combo is said to be highly selective towards the cancer cells. The SI values calculated for 
the extract-drug combo tested against MRC-5 showed that the combo was more selective 
towards the cancer cells compared to cancer cells as the values were more than 3.     
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4.3 Apoptosis Study 
4.3.1 Morphological Assessment of Apoptotic Cells byAcridine Orange (AO)- 
Ethidium Bromide (EB) Double Staining 
 The morphological changes of the HCT-116 and HT-29 cells treated with PW-E, 5-FU 
and their combination (at IC50 concentration) for 24 hours were observed by AO/EB 
staining and depicted in Figure 4.12 and Figure 4.13. The colon cancer cell HCT-116 
were treated at PW-E concentration of 1.5 µg/ml  and 5-Fu concentration of 1.5 µg/ml  
respectively and PW-E/5-FU combination concentration of 1.875+0.625 µg/ml 
respectively. For HT-29 cell line,the concentration of PW-E used was 0.03 µg/ml, 
concentration of 5-Fu were at 19.0 µg/ml while PW-E/5-Fu combination were 0.03+10.0 
µg/ml respectively. The cells were then classified as apoptotic, necrotic, or live (viable). 
Apoptotic cells will have condensed chromatin which gives several green coloured nuclei 
while the necrotic cells would be stained red. Cells that are still alive will have a round 
and green coloured nuclei with intact DNA and nucleus and will not stain as brightly as 
apoptotic cells.  
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As shown in Figure 4.12 and Figure 4.13, the control cells (cells without addition 
of any test agent) have cytoplasm and nucleus that are smoother and uniformly bright 
green.  Cells treated with extract, drug and drug-extract combo demonstrated some signs 
of apoptotic cells. Cells underwent apotosis showing morphological changes include 
shrinkage of cells and nuclear condensation and fragmentation. The treated cells showed 
brightly stained nucleus with highly condensed chromatin and were uniformly 
fluorescent. The condensed chromatin were observed to be either in the form of crescents 
around the periphery of the nucleus or the entire chromatin  present as one or a group of 
featureless, bright spherical beads. Less red stained cells were observed in the treated 
cells, which means that the cell death occurs primarily through apoptosis instead of 
necrosis.  
 
White arrows in Figure 4.12 and 4.13  indicated  live cells where it was observed 
that the nuclei of the cells are uniformly stained green. The green arrows indicated 
brightly green stained condensed chromatin. The purple arrows indicated the blebbing of 
the cell membrane, also an indicator of apoptosis. The red arrows showed the loss of 
membrane shape while the blue arrow showed necrotic cells. 
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(A) Untreated HCT-116 cells 
 
(B) HCT-116 cells treated with PW-E (1.5 
µg/ml) 
 
 
(C) HCT-116 cells treated with 5-FU (1.5 
µg/ml) 
 
(D) HCT-116 cells treated with             
PW-E/5-FU combo (1.875+0.625 
µg/ml) 
Figure 4.12: Morphological observation of HCT-116 treated with PW-E, 5-FU and      
PW-E/5-FU combo after stained with AO/EB ( magnifications 200 ×). White arrows in 
indicated  live cells where it was observed that the nuclei of the cells are uniformly stained 
green. The green arrows indicated brightly green stained condensed chromatin. The 
purple arrows indicated the blebbing of the cell membrane, also an indicator of apoptosis. 
The red arrows showed the loss of membrane shape while the blue arrow showed necrotic 
cells. Images are representatives from three independent experiments. 
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(A) Untreated HT-29 cells 
 
(B) HT-29 cells treated with PW-E (0.03 
µg/ml) 
 
 
(C) HT-29 cells treated with 5-FU (19.0 
µg/ml) 
 
(D) HT-29 cells treated with PW-E/5-FU 
combo (0.03+10.0µg/ml) 
 
Figure 4.13: Morphological observation of HT-29 treated with PW-E, 5-FU and             
PW-E/5-FU combo after stained with AO/EB ( magnifications 200 ×). White arrows in 
indicated  live cells where it was observed that the nuclei of the cells are uniformly stained 
green. The green arrows indicated brightly green stained condensed chromatin. The 
purple arrows indicated the blebbing of the cell membrane, also an indicator of apoptosis. 
The red arrows showed the loss of membrane shape while the blue arrow showed necrotic 
cells. Images are representatives from three independent experiments. 
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4.3.2 Caspase-3 Activation Determination 
  The intracellular levels of caspase-3, which plays a central role in mediating 
apoptotic responses (Nieves-Neira & Pommier, 1999) were measured to ascertain 
whether the cytotoxic activity could be dependent by the activation of the caspase-3  
protein. The intracellular levels of caspase-3 in HCT-116 and HT-29 cells were measured 
after being induced with PW-E, 5-FU and PW-E/5-FU combination. Following 48 hours 
treatment of HCT-116 and HT-29 cells with the respective IC50 concentrations of  PW-E, 
5-FU and PW-E/5-FU combination, caspase-3 activities were then measured and 
compared with control cells (without addition of any test agent). The colon cancer cell 
HCT-116 were treated at PW-E concentration of 1.5 µg/ml  and 5-Fu concentration of 1.5 
µg/ml  respectively and PW-E/5-FU combination concentration of 1.875+0.625 µg/ml 
respectively. For HT-29 cell line,the concentration of PW-E used was 0.03 µg/ml, 
concentration of 5-Fu were at 19.0 µg/ml while PW-E/5-Fu combination were 0.03+10.0 
µg/ml respectively. 
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Figure 4.14: Caspase-3 activation in HCT-116 cancer cells with and without addition of 
different test agents and analysed using Caspase-3 DEVD-R110 Fluorometric and 
Colorimetric assay kit. The values are expressed as percentage mean ± S.D compared 
with control from three independent experiments. PW-E: P. watsonii ethyl acetate extract; 
5-FU: 5-Fluorouracil, PW-E/5-FU combo at ratio 3:1. 5-Fu (5-Fluorouracil) = 93 ± 7 %, 
PW-E (P. watsonii ethyl acetate extract) = 126 ± 4 % and PW-E+5-Fu = 112 ± 8 %. (* 
indicates a significant difference from the control (p < 0.05). 
 
  As shown on Figure 4.14, HCT-116 cells when treated with PW-E alone exhibited 
increment in caspase-3 activity ranging from 1.23 to 1.51-folds higher compared to 
untreated cells. The caspase-3 activity in cell-treated with 5-FU alone ranges from 1.04 
and 1.26-folds higher than untreated cells. Caspase-3 activation are even higher and 
increased in HCT-116 cells-treated with  PW-E/5-FU combo, where the increment 
ranging from 1.12-folds to 1.61 folds.  
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Figure 4.15:Caspase-3 activation in HT-29 cancer cells with and without addition of 
different test agents and analysed using Caspase-3 DEVD-R110 Fluorometric and 
Colorimetric assay kit. The values are expressed as percentage mean ± S.D compared 
with control from three independent experiments. PW-E: P. watsonii ethyl acetate extract; 
5-FU: 5-Fluorouracil, PW-E/5-FU combo at PW-E and 5-FU concentration of 0.03:10.0. 
5-Fu = 118 ± 23%, PW-E (P. watsonii ethyl acetate extract) = 135 ± 25 % and PW-E+5-Fu 
= 191 ± 9%. (* indicates a significant difference from the control (p < 0.05). 
 
As can be seen in Figure 4.15, when HT-29 cells were treated with 5-FU alone, 
the caspase-3 activity increased by about 1.09-folds to1.17-folds, while when treated with 
PW-E, the caspase-3 activity increased by about 1.29-folds to 1.43-folds when compared 
to untreated cells. However, the highest increment of  caspase-3 activity can be observed 
when HT-29 cells were treated with the combination of PW-E and 5-FU, where the 
increment were ranging from 1.52-folds to 1.91-folds when compared to untreated cells. 
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CHAPTER 5: DISCUSSION 
 
5.1 LC-MS/MS Analysis of P. watsonii Ethyl Acetate Extract 
In this study, LC-MS/MS analysis was done to identify the major compounds 
present in P. watsonii ethyl acetate extract. LC-MS/MS was chosen for the compound 
analysis due to the technique’s ability to analyse a wide range of plant metabolites 
including secondary metabolites such as benzoids, alkaloids, flavonoids, isoprenes, 
terpenes and glucosinolates (Hill & Roessner, 2015). It can also detect highly polar and/or 
higher molecular weight molecules. In this present study, it was indentified that the P. 
watsonii ethyl acetate extract contains quercetin, kaempferol rhamnoside, kaempferol 
glucoside, ellagic acid, hyperin, strictinin isomer, strictinin, galloyl HHDP hexoside and 
also gallic acid. These compounds detected may be responsible for the observed cytotoxic 
activity of P. watsonii in this present work. 
 
Flavonoid is one of the major compounds identified in P. watsonii ethyl acetate 
extract. The flavonoids identified are quercetin, kaempferol rhamnoside and kaempferol 
glucoside and hyperin. Kuo, (1997) stated that flavonoids can be further classified into 
flavonols, flavones, flavanes, isoflavanes and flavanols. Depending on their biological 
activities, flavonoids can play a role in human cancer prevention. Among flavonoids, 
quercetin is considered an excellent free-radical scavenger, even if such an activity 
strongly depends on the intracellular availability of reduced glutathione (Gibellini et al., 
2011). Besides its potent antioxidant activity, quercetin also exerts a direct, pro-apoptotic 
effect in cancer cells, and blocks the growth of several human cancer cell lines at different 
phases of the cell cycle and this findings have been recorded in cellular and animal models 
(Gibellini et al., 2011). Quercetin has also been found to exert no damage towards normal, 
non transformed cells but exert high toxicity on cancer cells (Gibellini et al., 2011) which 
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could explain P. watsonii ethyl acetate extract selectivity towards cancer cells compared 
to normal cells. Kaempferol, which was also identified to be present in P. watsonii ethyl 
acetate extract is also known to have antioxidant activity and used for cyto-protection, 
where it protects cells from harmful agents (Huang et al., 2010). Studies have also 
reported that kaempferol has anti-proliferation activity and induces apoptosis in various 
human cancer cell lines in vitro such as prostate cancer (De Leo et al., 2006), colon cancer 
(Mutoh et al., 2000), oral cavity cancer (Kim et al., 2005) and leukaemia (Marfe et al., 
2009). 
 
Besides flavonoids, other phenolic compounds identified in P. watsonii ethyl 
acetate extract are ellagic acid, galloyl HHDP hexoside and gallic acid. Various studies 
had shown that phenolic compounds exerted antitumour properties by inhibiting the 
growth of the cells, inducing cell-cycle arrest, and exerting pro-apoptotic effects on colon 
cancer cells (Larrosa et al., 2006; Kern et al., 2007; Gonzalez et al., 2009). Ellagic acid 
derived from plants had also been proveen to be a potent anti-cancer agent (Das et al., 
1984). Ellagic acid has been hypothesized to target NF-kB, cyclin D1, p21cip1/waf1 and 
p53 (Aggarwal & Shishoida, 2006). Ca Ski cervival carcinoma cells, Caco-2 colon cells 
and MCF-7 breast cells are some of the cancer cells that have been reported to be 
susceptible to ellagic acid as it possesses growth inhibiting properties and promotes 
apoptosis in the cancer cells (Ramasamy et al., 2012). 
 
5.2 Cytotoxic Activity of P. watsonii, 5-FU and P. watsonii-5-FU Combination 
The search for an effective treatment for  colorectal cancer  (CRC) is a vital matter 
as it is the third most common cancer that causes death in the world. Despite early 
treatment by surgery, about  25 % experience post-operative relapse (Galizia  et al., 
2013). 5-Fluorouracil (5-FU) is currently considered a key drug in clinical 
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chemotherapeutic of CRC. However, several issues arise with the use of 5-FU in CRC 
treatment such as short half-life of 5-FU  and its resistance and severe side effects to the 
patients whose taking this drug (Li et al., 2009).  Many studies had been carried out in 
improvement of 5-FU in CRC treatment and overcome the problems associated with the 
use of 5-FU. 
 
New strategies are needed to overcome the disadvantages of 5-FU and other 
chemotherapy drugs in clinical application. One of the means is by combination therapy 
which combines the chemotherapy drug with natural product agents, such as plant extract 
or compound. In this approach, natural product-derived extract or compound is combined 
with the chemotherapy conventional drug to enhance the cytotoxicity and improve the 
effectiveness of these drugs. This combination may enhance or lessen the cytotoxicity 
effects compared to when being used in a single dosage form. Combinations between 
plant active ingredients with conventional anti-cancer drug are becoming a new target in 
drug delivery (Ng et al., 2014). 
 
Plant extracts have fewer side effects compared to chemotherapy drugs as it is 
loaded with natural secondary metabolites and other phytochemicals. In addition, 
minimum cytotoxicity towards normal cells and synergistic interaction between anti-
cancer drug-plant extract combination have been shown in laboratory studies (Ng et al., 
2014). Li et al. (2009) also reported that chemo-adjuvant compounds that have the 
potential to inhibit the growth of cancer cells, also can reduce chemotherapy-induced 
toxicity. By identifying potential non-toxic plant extracts, and further combining it with 
5-FU, the cytotoxicity effects of the combination towards cancer cells can be analysed 
and this will be an important step in enhancing and improving CRC chemotherapy (Li et 
al., 2009). 
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 In this present study, the Neutral Red Uptake Cytotoxic Assay was used to 
evaluate the cytotoxic activity of P. watsonii ethyl acetate extract, 5-FU and their 
combination on human colon cancer cells, HCT-116 and HT-29 cells. This is one of the 
most commonly used cytotoxicity assays and it provides a quantitative estimation of the 
number of viable cells in a culture based on the ability of viable cells to incorporate and 
bind the supravital dye neutral red in the lysosomes (Repetto et al., 2008). 
 
 P. watsonii ethyl acetate extract showed a good cytotoxicity against both colon 
cancer cells compared to 5-FU. When both extract and 5-FU were combined, it can be 
clearly seen that the extract-drug combination synergistically inhibits the growth of both 
colon cancer with less concentration of 5-FU was needed for an effective cells growth 
inhibition. A literature survey indicated that there are no study have been reported on the 
combination effect of P. watsonii and 5-FU on cytotoxicity. Therefore, the current 
information studies were compared with other work reported on the combination effects 
of plant-derived natural product with 5-FU in on colon cancer cells.  
 
In this present study, the cytotoxicity of PW-E/5-Fu combination against HCT-116 
and HT-29 cell lines and human lung fibroblast MRC-5 were also compared and stimulating 
outcome were found. When 5-Fu were combined with PW-E, the Selectivity Index (SI), the 
SI values calculated for the extract-drug combo tested against MRC-5 showed that the combo 
was more selective towards the cancer cells compared to normal cells as the value was more 
than 3. SI value is and indicator to measure the safety of extract/drug on non-cancerous cells. 
The result showed that the drug-extract combination was more selective towards cancer cells 
compared to normal cells. Since 5-Fu is known to cause undesireable side effects towards 
normal cells and also towards patients receiving treatment (Li et al., 2009), the combination 
of PW-E/5-Fu may offer more bearable treatment to patients under treatment with 5-Fu. P. 
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watsonii extracts have also been reported to be more selective toward cancer cells compared 
to normal cells (Ramasamy et al., 2012; Ramasamy et al., 2013). Thus, more study could be 
done to find out the effectiveness of drug-extract combination in killing cancer cells with less 
impact towards normal cells. 
 
Clinical applications of 5-FU have been greatly limited due to drug resistance 
(Zhang et al., 2008). Resistance to 5-FU is a multifactorial event (Zhang et al., 2008). 
There are reports stating that 5-FU depends on the p53 tumour suppressor protein to 
trigger apoptosis (Pritchard et al., 1998; Bunz et al., 1999; Petak et al., 2000; Borralho et 
al., 2007). p53 is a tumour suppressor protein that aids in regulating feedback towards 5-
FU. If p53 protein is disrupted, it will cause the colon cancer cells to be resistant to 5-FU 
and cancer cells will fail to undergo apoptosis and cell cycle arrest (Mader et al., 1998; 
Bunz et al., 1999; Borralho et al., 2007; Ng et al., 2014). The colon cancer cell line used 
in this study are HCT-116 and HT-29 cell lines. HT-29 cell lines, as tested with 5-FU in 
this study requires higher concentration of 5-FU to be able to achieve 50 % inhibition 
compared to HCT-116. This was because HT-29 was able to adapt and resist against the 
cytotoxicity of 5-FU through the activation of survival autophagy and the lack of wild-
type p53. However, when 5-FU was combined with PW-E, the concentration of 5-FU 
needed to achieve the same 50 % inhibition was reduced. By understanding more on the 
reduced resistance of HT-29 towards 5-FU and PW-E combination, CRC chemotherapy 
can further be enhanced and improved.  
 
Carnesecchi et al. (2004) reported that geraniol, an acyclic dietary monoterpene 
found in aromatic herb oils, increases the cytotoxicity of 5-FU against TC-118 human 
tumours transplanted in Swiss nu/nu mice. The combination also enhances the drug 
uptake of the transplanted cell. In the present study, the cytotoxicity of  5-FU against 
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HCT-116 and HT-29 colon cancer cell lines were increased when the drug was combined 
with P. watsonii ethyl acetate extract. Study by Fishbein et al. (2009) also showed that 
combination of  extract of Panax ginseng C. A. Meyer (Asian ginseng) with 5-FU 
increased the anti-proliferative effect towards human colon HCT-116 cancer cells, and 
the effect was significantly higher when compared with 5-FU and extract tested 
individually on the same colon cancer cells. Similarly, in a study done by Wang et al. 
(2007), anti-proliferative effects on HCT-116 cell were also significantly enhanced by the 
combination of flower extract of Panax notoginseng with 5-FU, when compared to cells 
treated with single dosage of the extract and 5-FU. A study by Tang et al. (2015) also 
showed that when 5-FU was combined with triptolide, a diterpenoid tripoxide derived 
from the herb Tripterygium wilfordii, the proliferation of HT-29 cell lines was 
significantly inhibited. The current results on the cytotoxic activity of P. watsonii and 5-
FU combination had also shown that it enhanced the anti-proliferative effect of 5-FU on 
both HCT-116 and HT-29 cells compared to that of cells treated with the drug alone. 
 
Combination of plant-derived extract and drug also had been proven to reverse the 
resistance of colon cancer cells towards 5-FU. In a study done by Gonzàlez-Vallinas et 
al. (2013), supercritical fluid rosemary extract (SFRE) from Rosmarinus officinalis could 
sensitize the 5-FU resistant towards SW620 colon cancer cells by downregulating the 
expressions of enzymes related to 5-FU resistancy. When Real-Time Polymerase Chain 
Reaction (RT-PCR) was performed on the RNA extracted from the colon cancer cells 
after treatment with (Supuercritical fluid rosemary extract (SFRE) of R. officinalis , it 
showed that there is a downregulation of thymidylate synthetase and tropomyosin 1 genes 
indicating that the modulation of these genes might be involved in the enhancement of 
the effect of 5-FU in resistant SW620 colon cancer cells. Similarly, in this present study, 
the sensitization factor values  showed that the  combination of P. watsonii and 5-FU 
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increased the sensitivity of 5-FU towards both colon cancer cells.  Further studies to 
determine the mechanism of this resistance reversal by the P. watsonii and 5-FU 
combination is warranted.  
 
Cytotoxicity effect towards the colon cancer cells triggered by the combination 
between P. watsonii and 5-FU has also been shown by induction of apoptosis. The 
apoptotic activity in human gastric carcinoma cells was induced when gambogic acid, a 
resin exuded from the tree of Garcinia hanburyi tree was combined with 5-FU (Wang et 
al., 2009). Study done by Xu et al. (2013) also proved that the effect of apoptosis is 
induced when 5-FU is combined with extract of Scutellaria barbata D. Don (SBE). SBE  
also increase the apoptosis inducing effect when combined with low dose of 5-FU in both 
human hepatocellular Bel-7402 carcinoma cell and human colon HCT-8 cancer cells (Xu 
et al., 2013). In addition, Kodach et al. (2006) showed that violacin, a pigmnt isolated 
from Chromobacterium violaceum, when combined with 5-FU, also induces apoptosis 
and potentiates the cytotxic effect of 5-FU in HCT-116 colon cancer cell lines. The 
combinaton also increases the chemosensitivity of HCT-116 cells towards 5-FU. 5-FU 
alone cannot increase the chemosensitivity of the cell. In another study by Hwang et al.  
(2005) showed that genistein, a soy derived phytoestrogen belonging to the ‘isoflavone’ 
family, when combined with 5-FU, causes the reduction of survival signal Glut-1 and the 
elevation of pro-apoptotic p53 and p21 in HT-29 colon cancer cell lines. In the present 
study, combination of P. watsonii and 5-FU triggered the cell death by apoptosis 
induction in both HCT-116 and HT-29 cancer cells.  
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More research supports on effectiveness of  combined therapy between natural 
products and 5-FU in which the combination significantly synergizing the cytotoxic  
effect of 5-FU. The concept of dual therapy by combining the plant-derived extract and 
anti-cancer drug might decrease the dose-related toxicities such as nausea vomiting and 
frequently impede effective treatment (Forman, 1994; Wu et al., 2007).   
 
5.3 P. watsonii-5-FU Combination Analysis  
Combination between anti-cancer drug and extract/compound-derived natural 
product could yield three types of interaction, which are synergistic, antagonistic or 
additive. Synergism interaction is caused when the agents combination is more effective 
than each agent reacted individually, meaning one of the agents enhances the actions of 
the second drug. Antagonism is defined as the combination being less effective than the 
single agents, meaning that one of the agents counteracts the actions of the other 
(Bijnsdorp et al., 2011). Additive effect is the total effect caused by two substances in 
combination is the same as the sum of individual effects (Drees et al., 2005). There are 
various ways a combination and their interaction can be studied, which are, firstly  by 
combining  simultaneously or secondly by a sequential combination schedule (Bijnsdorp 
et al., 2011). In this present study, the first method is used, where combination and its 
interaction is studied by combining P. watsonii and 5-FU simulatenously. It is vital to test 
the potency of a combination in in vitro model, before clinical trials are done and to avert 
antagonistic actions. Nevertheless, it should be understood that sometimes, antagonistic 
interaction is actually desired, especially when one drug decreases the unwanted side 
effects of another drug (Bijnsdorp et al., 2011).  
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One of the most widely used methods to effectively measure quantitatively the 
dose–effect relationship of each drug alone and its combinations and the interaction occur 
is the median-drug effect analysis. By using this method, based on the drug cytotoxicity 
or growth inhibition curve, a combination index (CI) is then calculated. In this present 
study, the Compusyn 1.0 software was used to calculate the CI by taking the entire shape 
of the growth inhibition curve into account to determine whether the combination exert 
synergistic, antagonistic or additive interaction.  
 
According to the Compusyn 1.0 software CI < 1 indicates that the combination is 
able to react synergistically with each other. If  CI = 1, the combination results in additive 
interaction and if CI > 1, the interaction is antagonistic (Zhang et al., 2016). Based on this 
analysis, CI values obtained when P. watsonii and 5-FU combination tested on HCT-116 
and HT-29 colon cancer cells were both less than 1, meaning that the combination exerts 
synergistic interaction in inhibiting the growth of the cells. When 5-FU was combined 
with P. watsonii  in the treatment of both HCT-116 and HT-29 colon cancer cell, the total 
dose needed to reduce cell viability by  50 % was lower than that of 5-FU or P. watsonii  
alone, and this indicate a synergistic interaction occurred between both combination.  
Based on the Drug Reduction Index (DRI) analysis, which measure on how much (-fold) 
dose of the drug or agent in a synergistic combination may be reduced at a given effect 
level when compared to the dose of each drug or agent alone, the DRI values in both 
cancer cells is more than 1. This indicates that the dose of P. watsoni and 5-FU 
combination is favourable as the value of DRI > 1 shows that the combination is 
favourable in terms of clinical therapy (Chou, 2010). 
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The CI value is the natural law–based general expression of pharmacologic drug 
interactions and is revealed to be the simplest probable way for calculating synergism or 
antagonism. It featues efficiency in its equation simplicity, experimental designs analysis 
of data and reduces the experimental size of animals used or the number of patients 
needed for drug combination clinical trials. The future of drug combination studies have 
been made simpler and more efficient based on the general theory of the median-effect 
principle of the mass-action law, its CI algorithm, and its computerized simulation and 
have been broadly accepted in scientific application and the swift increase in citation 
numbers (Chou, 2010). 
 
5.4 Apoptosis  Assessment in Cells Treated with P. watsonii, 5-FU and P. watsonii-  
5-FU Combination 
One of the hallmarks of cancer is the ability of cancer cells to evade apoptosis 
(Hanahan & Weinberg, 2011). New strategies have been developed to restore abnormal 
apoptotic pathway and stop the proliferation of cancer cells. Some of the strategies are by 
targeting the BCl-2 family of proteins, p53, the IAPs and targeting caspases. The ability 
to induce apoptosis, or programmed cell death  in cancer cells or malignant tissues, is 
recognized as one of the effective approaches in cancer chemotherapy and a very vital 
characteristic of a possible anti-cancer drug (Panchal, 1998; Ramasamy et al., 2012). 
 
The morphological assessment of apoptotic cells was done via acridine orange/ 
ethidium bromide (AO/EB) double staining in order to investigate whether the cytotoxic 
effects of P. watsonii and 5-FU combination are exerted via apoptotic pathway in both 
HCT-116 and HT-29 colon cancer  cells. In this present study, the apoptotic cells were 
identified based on the cell morphological changes and differentiated between necrotic 
and viable cells by dye staining which was observed under fluorescence microscope. 
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Distinct apoptotic morphological changes in treated HCT-116 and HT-29 cells included 
the rounding up of cells, blebbing of the cell membrane, brightly green stained condensed 
chromatin, and loss of membrane shape. The viable cells  performed circular nuclei which 
were uniformly distributed in the center of the cell. The intact membranes and DNA of 
the viable and early apoptotic cells were stained with fluorescence green by  acridine 
orange (Liu et al., 2015).  
 
Ethidium bromide only enters the damaged membranes of cells such as late 
apoptotic and dead cells, releasing orange-red fluorescence when bound to concentrated 
DNA fragments or apoptotic bodies (Li et al., 2013). In addition, AO/EB double staining 
is also able to detect mild DNA injuries (Ghergi et al., 2003). In the past, fluorescent 
staining using AO alone has been used while the apoptosis detection using AO/EB double 
staining is a relatively new strategy (Lecoeur, 2002; Liu et al., 2015). The AO/EB double 
staining has further improved apoptosis detection and is able to differentiate between late 
apoptotic and dead cells compared to AO single staining (Liu et al., 2015). 
 
Apoptosis induction is frequently associated with the activation of caspases 
(Thornberry & Lazebnik, 1998; Nhan et al., 2006; Ramasamy et al., 2012). Caspases are 
a family of protease enzymes playing crucial roles in apoptosis as they are the initiators 
and executioners in the apoptotic pathway. In the present study, following the treatment 
of HCT-116 and HT-29 cells with P. watsonii and 5-FU combination, showed an 
increment in the activity of caspase-3 compared to when the cells without addition of any 
drug or extract and cells treated with the drug and extract individually. Extracts from 
different Phyllanthus species have been reported to show apoptosis induction by 
increasing caspase-3 activity in various cancer cell lines of different origins (Huang et al., 
2003; Liu et al., 2006; Abu Bakar et al., 2010).  
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The capability to control or modulate the life or death of a cell is recognized for its 
enormous potential in cancer therapy (Elmore, 2007). Studies are now continued to 
emphasize on the elucidation and analysis of the machinery of cell cycle and signaling 
pathways that control cell cycle arrest and apoptosis since abnormal machinery of the cell 
cycle has been associated with the beginning and the progression of cancer (Ramasamy 
et al., 2012). Extensive work needs to be done to find out on at which stage of the cell 
cycle does P. watsonii and 5-FU combination induces apoptosis. Further studies should 
be carried out in order to understand in depth  the mechanism of action of P. watsonii and 
5-FU combination on inhibiting the growth of the colon cancer  cells. 
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CHAPTER 6: CONCLUSION 
Nowadays, researchers have been focusing  on combination chemotherapy to 
overcome the drawbacks of conventional chemotherapy. One of the main reasons 
combination chemotherapy is applied is to reduce the probability of cancer cells 
developing resistency towards the drugs . Besides that, combination chemotherapy is also 
intended to maximize the efficacy of the drug while minimizing undesireable side effects 
through the delivery of lower drug doses. Combination chemotherapy has been linked to 
the improvement in patient’s compliance to treatments, overcome or delay multi-drug 
resistance, the development of additive or synergistic interaction effects between drugs 
and the reduction of drug concentration with subsequent diminishing of toxicity to healthy 
tissues. 
 
 The combination of drug and plant extract is the current potential approach in 
combination chemotherapy for the treatment of cancer. For thousands of years, plants 
have been used to treat illnesses, health disorders and prevent diseases. Plants extracts 
have fewer side effects compared to chemotherapy drugs as it is loaded with natural 
secondary metabolites and other phytochemicals and the usage of plant extract for many 
years had proven that they were relatively safe and may even improve the effectiveness 
of single dosage form of chemotherapeutic drugs. Due to its strong antioxidant activity, 
the synergistic combination of the plant-derived extract/compound with anticancer drugs 
is expected diminish toxicities towards normal and healthy cells, subsequently permitting 
the usage of anticancer drug at high doses with minimal side effects; maintaining the 
efficacy of the anticancer drug while reducing its concentration; and improving the 
sensitivity of anticancer drugs towards the cancer cells. 
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In this study, the cytotoxic effect of Phyllanthus watsonii ethyl acetate extract in 
combination with 5-Fluorouracil on two types of colon cancer cell lines which are HCT-
116 and the more 5-FU resistant HT-29 were investigated. This study revealed that the 
individual treatment of P. watsonii and 5-FU inhibited the growth of both HCT-116 and 
HT-29 cell lines in dose dependent manner while combination of 5-Fluorouracil with 
extract of  Phyllanthus watsonii had a potential to enhance the cytotoxicity effect on both 
human colon cancer cell lines. The combination also has a potential to reduce the 
resistency of HT-29 cell line towards 5-FU as less concentration of 5-FU was needed to 
achive the same inhibitory effect when 5-FU was combined with PW-E in this study. In 
addition, the combination index analysis through median-effect method showed that PW-
E-5-FU combination was able to reduce the dosage of individual 5-FU, in turn reducing 
toxicity while still gives out the same inhibitory efficacy on HCT-116 and HT-29 cell 
lines. The combination also showed greater selectivity towards colon cancer cells as 
opposed to normal cells. The result also indicates that both P. watsonii and 5-FU 
combination interacts synergistically towards inhibiting the growth of HCT-116 and HT-
29 and this is also a good indication of improvements on the effectiveness of the cells-
treated with 5-FU. The study also revealed that the potential cell death mechanism 
triggered by the P. watsonii and 5-FU combination is via apoptosis initiation through 
caspase-3 activation. 
 
Additional studies are warranted to determine at which cell cycle stage does the 
drug-extract combination induce apoptosis, and also to understand the interaction 
mechanism being involved in the apoptotic signaling pathway are induced by this 
combination. Studies should also be done whether the combination of 5-FU and PW-E 
could lessen the side effects caused by the use of 5-FU in cancer therapy. Testing using 
animal models (in vivo study) should also be considered as testing in vitro and in vivo are 
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under distinct difference. This is to learn if the dose reduction can be sustained in animal 
study or even true synergism can be attained. 
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APPENDIX 
Appendix A 
Cytotoxic Activity Raw Data 
Cytotoxic Activity of P. watsonii ethyl acetate extract, 5-FU and PW-E/5-FU 
Combination against HCT-116, HT-29 colon cancer cell lines and MRC-5 normal lung 
fibroblast cell. 
 
 
IC50 values (µg/ml) of P. watsonii ethyl acetate extract, 5-FU and PW-E/5-FU combo 
on HCT-116 cell line. 
 
 
Test agent 
IC50 value (µg/ml) 
Test 1 Test 2 Test 3 Averagea 
 
PW-Eb 
 
1.600808 
 
1.32972 
 
1.63596 
 
1.522163 ± 0.16 
 
5-FUc 
 
1.85802 
 
1.85632 
 
1.05097 
 
1.588437 ± 0.46 
 
PW-E/5-FUd 
 
1.43028 
 
1.75304 
 
1.26206 
 
1.48179 ± 0.25 
aData are represented as mean±SD from three independent experiments, triplicate each; bethyl acetate 
extract of P. watsonii; c5-Fluorouracil; dcombination at ratio 3:1. 
 
IC50 values (µg/ml) of P. watsonii ethyl acetate extract, 5-FU and PW-E/5-FU combo 
on HT-29 cell line. 
 
 
Test agent 
IC50 value (µg/ml) 
Test 1 Test 2 Test 3 Averagea 
 
PW-Eb 
 
0.03473 
 
0.02767 
 
0.02962 
 
0.03067 ± 0.003 
 
5-FUc 
 
21.5422 
 
18.1208 
 
19.44733 
 
19.70 ± 1.7 
 
PW-E/5-FUd 
 
0.03/10.0 
 
0.03/10.0 
 
0.03/10.0 
 
0.03/10.0 
aData are represented as mean±SD from three independent experiments, triplicate each; bethyl acetate 
extract of P. watsonii; c5-Fluorouracil; dcombination at concentration of PW-E/5-FU 0.03 and 10.0 µg.ml. 
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IC50 values (µg/ml) of P. watsonii ethyl acetate extract, 5-FU and PW-E/5-FU combo 
on MRC-5 cell line. 
 
Test agent 
IC50 value (µg/ml) 
Test 1 Test 2 Test 3 Averagea 
 
PW-Eb 
 
3.80 
 
3.57 
 
3.54 
 
3.65 ± 0.142 
 
5-FUc 
 
1749.78 
 
699.492 
 
2614.38 
 
1687.884 ±958  
 
 
PW-E/5-FUd 
 
3.64/100.00 
 
3.64/100.00 
 
3.64/100.00 
 
3.64/100.00 
aData are represented as mean±SD from three independent experiments, triplicate each; bethyl acetate 
extract of P. watsonii; c5-Fluorouracil; dcombination at concentration of PW-E/5-FU at 3.64 µg/ml of PW-
E and 100 µg/ml of 5-FU. 
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Appendix B 
 
The Mass Spectrum of strictinin in P. watsonii ethyl acetate extract 
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Appendix C 
 
The Mass Spectrum of strictinin isomer in P. watsonii ethyl acetate extract 
 99 
     
9
9
 
Appendix D 
  
The Mass Spectrum of strictinin isomer 2 in P. watsonii ethyl acetate extract 
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Appendix E 
 
The Mass Spectrum of quercetin in P. watsonii ethyl acetate extract 
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Appendix F 
 
The Mass Spectrum of kaempferol rhamnoside in P. watsonii ethyl acetate extract 
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Appendix G 
 
The Mass Spectrum of kaempferol glucoside in P. watsonii ethyl acetate extract 
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Appendix H 
  
The Mass Spectrum of hyperin in P. watsonii ethyl acetate extract 
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Appendix I 
 
The Mass Spectrum of galloyl HHDP hexoside in P. watsonii ethyl acetate extract 
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Appendix J 
 
The Mass Spectrum of gallic acid in P. watsonii ethyl acetate extract 
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Appendix K 
 
 The Mass Spectrum of ellagic acid in P. watsonii ethyl acetate extract 
